Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	transcription factor binding	JARID2 NCOA3 NCOR1 TOB2 HDAC6 NFIA ARID2 PCLO CRTC1 RUNX2 ARID1A MED12 SMAD4	4.11e-06	753	75	13	GO:0008134
GeneOntologyMolecularFunction	chromatin binding	JARID2 NCOA3 NCOR1 EP400 NFIA SUPT6H ASXL2 RUNX2 ARID1A MED12 NUP153 SMAD4	1.86e-05	739	75	12	GO:0003682
GeneOntologyMolecularFunction	peroxisome proliferator activated receptor binding	NCOA3 NCOR1 ASXL2	6.45e-05	21	75	3	GO:0042975
GeneOntologyMolecularFunction	transcription coactivator activity	NCOA3 KMT2C MAML2 DCC ARID1A MAML3 MED12	1.42e-04	303	75	7	GO:0003713
GeneOntologyMolecularFunction	transcription coregulator activity	NCOA3 NCOR1 KMT2C TOB2 MAML2 DCC ARID1A MAML3 MED12	2.50e-04	562	75	9	GO:0003712
GeneOntologyMolecularFunction	nuclear thyroid hormone receptor binding	NCOA3 NCOR1 MED12	2.80e-04	34	75	3	GO:0046966
GeneOntologyMolecularFunction	disaccharide binding	LGALS9B LGALS9	2.89e-04	7	75	2	GO:0048030
GeneOntologyMolecularFunction	DNA-binding transcription factor binding	NCOA3 NCOR1 TOB2 NFIA CRTC1 RUNX2 ARID1A MED12 SMAD4	3.23e-04	582	75	9	GO:0140297
GeneOntologyMolecularFunction	protein-macromolecule adaptor activity	ANKRD13D JARID2 NCOA3 NCOR1 KMT2C TOB2 EPC1 MAML2 DCC ARID1A MAML3 MED12 NUP153	3.51e-04	1160	75	13	GO:0030674
GeneOntologyMolecularFunction	galactoside binding	LGALS9B LGALS9	4.93e-04	9	75	2	GO:0016936
GeneOntologyMolecularFunction	nuclear receptor binding	NCOA3 NCOR1 TOB2 ARID1A MED12	6.93e-04	187	75	5	GO:0016922
GeneOntologyMolecularFunction	transcription corepressor binding	HDAC6 PCLO SMAD4	1.42e-03	59	75	3	GO:0001222
GeneOntologyMolecularFunction	molecular adaptor activity	ANKRD13D JARID2 NCOA3 NCOR1 KMT2C TOB2 EPC1 MAML2 DCC ARID1A MAML3 MED12 NUP153	1.50e-03	1356	75	13	GO:0060090
GeneOntologyMolecularFunction	nuclear vitamin D receptor binding	TOB2 MED12	2.05e-03	18	75	2	GO:0042809
GeneOntologyMolecularFunction	ubiquitin-modified protein reader activity	ANKRD13D JARID2	2.53e-03	20	75	2	GO:0140036
GeneOntologyMolecularFunction	oligosaccharide binding	LGALS9B LGALS9	2.53e-03	20	75	2	GO:0070492
GeneOntologyBiologicalProcess	positive regulation of transcription by RNA polymerase II	NCOA3 KMT2C USF3 NFIA LMO7 SUPT6H UBP1 ARID2 EPC1 CRTC1 PRKD1 ASXL2 MAML2 RUNX2 MAML3 MED12 SMAD4	5.27e-06	1390	73	17	GO:0045944
GeneOntologyBiologicalProcess	stress granule assembly	ATXN2L ATXN2 UBAP2L PRRC2C	7.81e-06	36	73	4	GO:0034063
GeneOntologyCellularComponent	nuclear protein-containing complex	JARID2 NCOA3 NCOR1 KMT2C HDAC6 EP400 UBAP2L SUPT6H ARID2 NPAP1 ASXL2 ARID1A SAP130 MED12 NUP153 SMAD4	2.42e-05	1377	75	16	GO:0140513
GeneOntologyCellularComponent	histone deacetylase complex	NCOR1 HDAC6 EP400 SAP130	2.48e-04	85	75	4	GO:0000118
GeneOntologyCellularComponent	cytoplasmic stress granule	ATXN2L ATXN2 UBAP2L PRRC2C	3.96e-04	96	75	4	GO:0010494
GeneOntologyCellularComponent	cytoplasmic ribonucleoprotein granule	ATXN2L TUT4 ATXN2 UBAP2L PRRC2C TNRC6B	4.11e-04	269	75	6	GO:0036464
GeneOntologyCellularComponent	ribonucleoprotein granule	ATXN2L TUT4 ATXN2 UBAP2L PRRC2C TNRC6B	5.79e-04	287	75	6	GO:0035770
GeneOntologyCellularComponent	PcG protein complex	JARID2 UBAP2L ASXL2	8.64e-04	52	75	3	GO:0031519
HumanPheno	Kyphosis	KMT2C COL6A3 GTPBP2 USF3 UBAP2L ARID2 NPAP1 ASXL2 RUNX2 HERC1 DCC ZMYM3 SMAD4	4.69e-07	510	27	13	HP:0002808
HumanPheno	Scoliosis	JARID2 KMT2C COL6A3 GTPBP2 USF3 UBAP2L ARID2 NPAP1 PRKD1 ASXL2 RUNX2 HERC1 DCC ARID1A MED12 ZMYM3 SMAD4	5.23e-06	1122	27	17	HP:0002650
HumanPheno	Abnormal curvature of the vertebral column	JARID2 KMT2C COL6A3 GTPBP2 USF3 UBAP2L ARID2 NPAP1 PRKD1 ASXL2 RUNX2 HERC1 DCC ARID1A MED12 ZMYM3 SMAD4	1.72e-05	1219	27	17	HP:0010674
HumanPheno	Macrocephaly	JARID2 KMT2C USF3 HDAC6 NFIA TNRC6B ASXL2 RUNX2 HERC1 MED12 SMAD4	1.86e-05	491	27	11	HP:0000256
HumanPheno	Increased head circumference	JARID2 KMT2C USF3 HDAC6 NFIA TNRC6B ASXL2 RUNX2 HERC1 MED12 SMAD4	2.21e-05	500	27	11	HP:0040194
HumanPheno	Thin upper lip vermilion	NFIA UBAP2L ARID2 NPAP1 TNRC6B ASXL2 ARID1A MED12 SMAD4	3.69e-05	339	27	9	HP:0000219
HumanPheno	Thin lips	NFIA UBAP2L ARID2 NPAP1 TNRC6B ASXL2 ARID1A MED12 SMAD4	3.69e-05	339	27	9	HP:0000213
HumanPheno	Thin vermilion border	NFIA UBAP2L ARID2 NPAP1 TNRC6B ASXL2 RUNX2 ARID1A MED12 SMAD4	3.99e-05	433	27	10	HP:0000233
HumanPheno	Hyperactivity	JARID2 NFIA UBAP2L ARID2 NPAP1 TNRC6B PRKD1 ARID1A MED12 ZMYM3 SMAD4	6.23e-05	558	27	11	HP:0000752
HumanPheno	Abnormality of upper lip vermillion	JARID2 NFIA UBAP2L ARID2 NPAP1 TNRC6B ASXL2 ARID1A MED12 SMAD4	7.25e-05	464	27	10	HP:0011339
HumanPheno	Attention deficit hyperactivity disorder	JARID2 NFIA UBAP2L ARID2 NPAP1 TNRC6B PRKD1 MED12 ZMYM3	1.73e-04	413	27	9	HP:0007018
HumanPheno	Short philtrum	JARID2 HDAC6 ARID2 RUNX2 ARID1A MED12 SMAD4	2.59e-04	253	27	7	HP:0000322
HumanPheno	Abnormal social development	JARID2 KMT2C NFIA UBAP2L ARID2 NPAP1 TNRC6B PRKD1 HERC1 ARID1A MED12 ZMYM3 SMAD4	2.86e-04	908	27	13	HP:0025732
HumanPheno	Abnormal eyebrow morphology	JARID2 KMT2C GTPBP2 UBAP2L ARID2 PRKD1 ASXL2 HERC1 ARID1A MED12 SMAD4	3.49e-04	674	27	11	HP:0000534
HumanPheno	Autistic behavior	JARID2 KMT2C USF3 UBAP2L ARID2 NPAP1 TNRC6B ARID1A MED12 ZMYM3 SMAD4	3.68e-04	678	27	11	HP:0000729
HumanPheno	Disinhibition	JARID2 KMT2C NFIA UBAP2L ARID2 NPAP1 TNRC6B PRKD1 ARID1A MED12 ZMYM3 SMAD4	3.97e-04	807	27	12	HP:0000734
HumanPheno	Inappropriate behavior	JARID2 KMT2C NFIA UBAP2L ARID2 NPAP1 TNRC6B PRKD1 ARID1A MED12 ZMYM3 SMAD4	3.97e-04	807	27	12	HP:0000719
HumanPheno	Abnormal response to social norms	JARID2 KMT2C NFIA UBAP2L ARID2 NPAP1 TNRC6B PRKD1 ARID1A MED12 ZMYM3 SMAD4	3.97e-04	807	27	12	HP:5200123
HumanPheno	Social disinhibition	JARID2 KMT2C NFIA UBAP2L ARID2 NPAP1 TNRC6B PRKD1 ARID1A MED12 ZMYM3 SMAD4	3.97e-04	807	27	12	HP:5200029
HumanPheno	Metopic synostosis	NFIA UBAP2L HERC1	3.98e-04	28	27	3	HP:0011330
HumanPheno	Cupped ear	UBAP2L ASXL2 MED12 ZMYM3	4.28e-04	69	27	4	HP:0000378
HumanPheno	Hypoplastic iliac wing	HDAC6 RUNX2 SMAD4	5.41e-04	31	27	3	HP:0002866
HumanPheno	Abnormality of refraction	KMT2C GTPBP2 USF3 UBAP2L ARID2 NPAP1 HERC1 ARID1A MED12 ZMYM3 SMAD4	5.47e-04	709	27	11	HP:0000539
Domain	PAM2	ATXN2L TOB2 ATXN2	4.93e-06	9	74	3	PF07145
Domain	Ataxin-2_C	ATXN2L TOB2 ATXN2	4.93e-06	9	74	3	IPR009818
Domain	ArfGap	SMAP1 AGAP7P AGAP4 AGAP6	5.00e-06	29	74	4	SM00105
Domain	ArfGap	SMAP1 AGAP7P AGAP4 AGAP6	5.00e-06	29	74	4	PF01412
Domain	ARFGAP	SMAP1 AGAP7P AGAP4 AGAP6	5.00e-06	29	74	4	PS50115
Domain	ArfGAP	SMAP1 AGAP7P AGAP4 AGAP6	5.00e-06	29	74	4	IPR001164
Domain	SM_dom_ATX	ATXN2L ATXN2	1.55e-05	2	74	2	IPR025852
Domain	LsmAD	ATXN2L ATXN2	1.55e-05	2	74	2	PF06741
Domain	LsmAD_domain	ATXN2L ATXN2	1.55e-05	2	74	2	IPR009604
Domain	SM-ATX	ATXN2L ATXN2	1.55e-05	2	74	2	PF14438
Domain	LsmAD	ATXN2L ATXN2	1.55e-05	2	74	2	SM01272
Domain	-	JARID2 ARID2 ARID1A	2.63e-05	15	74	3	1.10.150.60
Domain	BRIGHT	JARID2 ARID2 ARID1A	2.63e-05	15	74	3	SM00501
Domain	ARID_dom	JARID2 ARID2 ARID1A	2.63e-05	15	74	3	IPR001606
Domain	ARID	JARID2 ARID2 ARID1A	2.63e-05	15	74	3	PS51011
Domain	ARID	JARID2 ARID2 ARID1A	2.63e-05	15	74	3	PF01388
Domain	Neuroggenic_mastermind-like_N	MAML2 MAML3	4.63e-05	3	74	2	IPR019082
Domain	MamL-1	MAML2 MAML3	4.63e-05	3	74	2	PF09596
Domain	MamL-1	MAML2 MAML3	4.63e-05	3	74	2	SM01275
Domain	MAD_homology1_Dwarfin-type	NFIA SMAD4	9.96e-04	12	74	2	IPR003619
Domain	DWA	NFIA SMAD4	9.96e-04	12	74	2	SM00523
Domain	MH1	NFIA SMAD4	9.96e-04	12	74	2	PF03165
Domain	Gal-bind_lectin	LGALS9B LGALS9	1.57e-03	15	74	2	PF00337
Domain	Gal-bind_lectin	LGALS9B LGALS9	1.57e-03	15	74	2	SM00908
Domain	GALECTIN	LGALS9B LGALS9	1.57e-03	15	74	2	PS51304
Domain	Galectin_CRD	LGALS9B LGALS9	1.57e-03	15	74	2	IPR001079
Domain	GLECT	LGALS9B LGALS9	1.57e-03	15	74	2	SM00276
Domain	Znf_FYVE_PHD	KMT2C MTMR4 SYTL3 PCLO	2.77e-03	147	74	4	IPR011011
Domain	PH	TRIOBP PRKD1 AGAP7P AGAP4 AGAP6	4.92e-03	278	74	5	SM00233
Domain	PH_DOMAIN	TRIOBP PRKD1 AGAP7P AGAP4 AGAP6	5.00e-03	279	74	5	PS50003
Domain	PH_domain	TRIOBP PRKD1 AGAP7P AGAP4 AGAP6	5.07e-03	280	74	5	IPR001849
Domain	-	CELSR2 LGALS9B LGALS9	6.37e-03	95	74	3	2.60.120.200
Domain	PH_dom-like	MTMR4 TRIOBP PRKD1 AGAP7P AGAP4 AGAP6	6.83e-03	426	74	6	IPR011993
Pathway	REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY	NCOR1 HDAC6 MAML2 MAML3	4.26e-06	28	56	4	M6177
Pathway	WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA	NCOR1 KMT2C TLK1 ARID1A MAML3	5.68e-06	65	56	5	M39682
Pathway	WP_BONE_MORPHOGENIC_PROTEIN_SIGNALING_AND_REGULATION	TOB2 RUNX2 SMAD4	1.27e-05	12	56	3	M39519
Pathway	REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	NCOR1 HDAC6 MAML2 MAML3	3.82e-05	48	56	4	M611
Pathway	REACTOME_SIGNALING_BY_NOTCH1_PEST_DOMAIN_MUTANTS_IN_CANCER	NCOR1 HDAC6 MAML2 MAML3	8.08e-05	58	56	4	M29616
Pathway	BIOCARTA_VDR_PATHWAY	NCOA3 NCOR1 ARID1A	8.67e-05	22	56	3	MM1370
Pathway	REACTOME_CHROMATIN_MODIFYING_ENZYMES	NCOR1 KMT2C EP400 ARID2 EPC1 ARID1A SAP130	9.53e-05	272	56	7	M29619
Pathway	REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY	HDAC6 MAML2 MAML3	9.94e-05	23	56	3	MM14954
Pathway	REACTOME_SIGNALING_BY_NOTCH1	NCOR1 HDAC6 MAML2 MAML3	2.09e-04	74	56	4	M616
Pathway	REACTOME_RUNX2_REGULATES_BONE_DEVELOPMENT	HDAC6 RUNX2 SMAD4	2.47e-04	31	56	3	M27805
Pathway	WP_DELTANOTCH_SIGNALING_PATHWAY	NCOR1 MAML2 MAML3 SMAD4	3.10e-04	82	56	4	MM15922
Pathway	REACTOME_RUNX2_REGULATES_BONE_DEVELOPMENT	RUNX2 SMAD4	3.21e-04	7	56	2	MM15533
Pathway	WP_ANDROGEN_RECEPTOR_SIGNALING	NCOA3 NCOR1 RUNX2 SMAD4	4.62e-04	91	56	4	M39700
Pathway	REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING	MAML2 MAML3	6.83e-04	10	56	2	MM15535
Pathway	PID_HES_HEY_PATHWAY	NCOR1 MAML2 RUNX2	9.05e-04	48	56	3	M288
Pathway	REACTOME_ADIPOGENESIS	NCOA3 NCOR1 MED12 SMAD4	9.43e-04	110	56	4	M48259
Pathway	REACTOME_NOTCH2_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	MAML2 MAML3	9.97e-04	12	56	2	M27159
Pathway	KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00380	MAML2 MAML3	9.97e-04	12	56	2	M47532
Pathway	KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00381	MAML2 MAML3	9.97e-04	12	56	2	M47533
Pathway	KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00382	MAML2 MAML3	1.18e-03	13	56	2	M47534
Pathway	REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING	MAML2 MAML3	1.37e-03	14	56	2	M27808
Pathway	WP_RUBINSTEINTAYBI_SYNDROME_1	NCOA3 SMAD4	1.57e-03	15	56	2	M48323
Pathway	PID_SMAD2_3PATHWAY	NUP153 SMAD4	1.79e-03	16	56	2	M228
Pathway	REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS	MAML2 MAML3	1.79e-03	16	56	2	M27121
Pathway	WP_NOTCH_SIGNALING_WP61	NCOR1 MAML2 MAML3	1.82e-03	61	56	3	M39540
Pathway	REACTOME_GENE_EXPRESSION_TRANSCRIPTION	JARID2 HDAC6 SUPT6H EPC1 TNRC6B MAML2 RUNX2 ARID1A MAML3 NUP153 SMAD4	1.99e-03	1022	56	11	MM15436
Pathway	PID_ERA_GENOMIC_PATHWAY	NCOA3 NCOR1 SMAD4	2.08e-03	64	56	3	M200
Pathway	REACTOME_SIGNALING_BY_NOTCH1	MAML2 MAML3	2.28e-03	18	56	2	MM14775
Pathway	REACTOME_DISEASES_OF_SIGNAL_TRANSDUCTION_BY_GROWTH_FACTOR_RECEPTORS_AND_SECOND_MESSENGERS	NCOR1 HDAC6 LMO7 MAML2 TFG MAML3 SMAD4	2.30e-03	464	56	7	M27547
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX1	KMT2C ARID2 TNRC6B RUNX2 ARID1A	2.45e-03	237	56	5	M27786
Pathway	WP_TGFBETA_SIGNALING_IN_THYROID_CELLS_FOR_EPITHELIALMESENCHYMAL_TRANSITION	RUNX2 SMAD4	2.54e-03	19	56	2	M39370
Pathway	BIOCARTA_TOB1_PATHWAY	TOB2 SMAD4	2.54e-03	19	56	2	M18215
Pathway	BIOCARTA_TOB1_PATHWAY	TOB2 SMAD4	2.54e-03	19	56	2	MM1490
Pathway	REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION	NCOR1 KMT2C HDAC6 SUPT6H ARID2 EPC1 TNRC6B MAML2 RUNX2 ARID1A MAML3 MED12 SMAD4	2.57e-03	1387	56	13	M734
Pubmed	Interaction network of human early embryonic transcription factors.	NCOA3 NCOR1 KMT2C EP400 NFIA ARID2 EPC1 KPRP PROSER1 ASXL2 ARID1A MED12 ZMYM3	7.78e-13	351	76	13	38297188
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	KMT2C GGA2 EP400 LMO7 SUPT6H NAV2 TRIOBP CRTC1 MAML2 CEP126 AGAP7P AGAP4 AGAP6	1.29e-10	529	76	13	14621295
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	ATXN2L NCOA3 NCOR1 KMT2C TLK1 EP400 ATXN2 PRRC2C ARID2 ZNF207 ASXL2 RUNX2 ARID1A SAP130 MED12 ZMYM3 NUP153	1.93e-10	1103	76	17	34189442
Pubmed	Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation.	NCOA3 NCOR1 KMT2C ATXN2 PRRC2C TNRC6B ZNF207 ARID1A TFG SAP130 MAML3 NUP153	3.33e-10	457	76	12	32344865
Pubmed	Human transcription factor protein interaction networks.	NCOA3 NCOR1 KMT2C EP400 NFIA ATXN2 UBAP2L DTNA PRRC2C ARID2 EPC1 TNRC6B PROSER1 ASXL2 HERC1 ARID1A SAP130 ZMYM3	1.30e-09	1429	76	18	35140242
Pubmed	cDNAs with long CAG trinucleotide repeats from human brain.	NCOA3 EP400 ATXN2 MAML3 MED12	1.42e-09	23	76	5	9225980
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	ATXN2L NCOR1 KMT2C EP400 LMO7 UBAP2L PRRC2C ARID2 TNRC6B ARID1A SAP130 MED12	2.63e-09	549	76	12	38280479
Pubmed	t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway.	CRTC1 MAML2 MAML3	1.00e-08	3	76	3	12539049
Pubmed	Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.	NCOA3 NCOR1 EP400 NFIA ARID1A SAP130	2.94e-08	83	76	6	28794006
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	NCOR1 TOB2 USF3 EP400 ATXN2 ARID2 NDFIP2 MAML2 SAP130 NUP153	3.47e-08	430	76	10	35044719
Pubmed	Tagging genes with cassette-exchange sites.	NCOA3 NCOR1 KMT2C TLK1 UBP1 PRRC2C NAV2 TFG SMAD4	5.18e-08	335	76	9	15741177
Pubmed	A novel role for the peptidyl-prolyl cis-trans isomerase Cyclophilin A in DNA-repair following replication fork stalling via the MRE11-RAD50-NBS1 complex.	SMAP1 EP400 ARID2 KPRP TNRC6B ZNF207 ARID1A TFG SAP130 MED12	8.27e-08	472	76	10	38943005
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	KLHL29 KMT2C TLK1 USF3 TUT4 NFIA ATXN2 UBAP2L DTNA SUPT6H TRIOBP TNRC6B PRKD1 ARID1A SAP130 MAML3	1.12e-07	1489	76	16	28611215
Pubmed	Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.	NCOA3 NCOR1 EP400 NFIA EPC1 ARID1A SAP130 MED12	1.34e-07	268	76	8	33640491
Pubmed	Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.	NCOR1 HDAC6 EP400 NFIA UBP1 PRRC2C EPC1 BEND4 ASXL2 SAP130 ZMYM3 SMAD4	3.39e-07	857	76	12	25609649
Pubmed	RNF138 inhibits late inflammatory gene transcription through degradation of SMARCC1 of the SWI/SNF complex.	ATXN2L UBAP2L ARID2 ARID1A	4.80e-07	29	76	4	36800290
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	ATXN2L NCOR1 EP400 LMO7 DTNA SUPT6H PRRC2C ARID2 ARID1A ZMYM3	6.20e-07	588	76	10	38580884
Pubmed	H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.	NCOR1 KMT2C EP400 NFIA LMO7 SUPT6H UBP1 EPC1 ASXL2 ARID1A SAP130 ZMYM3 NUP153 SMAD4	7.23e-07	1294	76	14	30804502
Pubmed	Complementary quantitative proteomics reveals that transcription factor AP-4 mediates E-box-dependent complex formation for transcriptional repression of HDM2.	NFIA UBP1 ARID2 ARID1A SAP130	7.62e-07	77	76	5	19505873
Pubmed	New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules.	ATXN2L TUT4 ATXN2 UBAP2L PRRC2C PCLO TNRC6B PRKD1 MED12	7.73e-07	462	76	9	31138677
Pubmed	GGAPs, a new family of bifunctional GTP-binding and GTPase-activating proteins.	AGAP7P AGAP4 AGAP6	8.34e-07	9	76	3	12640130
Pubmed	A direct physical interaction between Nanog and Sox2 regulates embryonic stem cell self-renewal.	NCOR1 KMT2C EP400 SUPT6H ARID1A SAP130	8.47e-07	146	76	6	23892456
Pubmed	Dynamic Protein Interactions of the Polycomb Repressive Complex 2 during Differentiation of Pluripotent Cells.	JARID2 NCOA3 KMT2C EP400 UBAP2L SUPT6H PRRC2C ZNF207 ARID1A	8.75e-07	469	76	9	27634302
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	ATXN2L NCOA3 NCOR1 TLK1 HDAC6 EP400 NFIA LMO7 UBAP2L ZMYM3 NUP153	9.51e-07	774	76	11	15302935
Pubmed	AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release.	AGAP7P AGAP4 AGAP6	1.19e-06	10	76	3	20664521
Pubmed	The Epigenetic Factor Landscape of Developing Neocortex Is Regulated by Transcription Factors Pax6→ Tbr2→ Tbr1.	JARID2 HDAC6 EP400 ARID2 EPC1 ARID1A	1.29e-06	157	76	6	30186101
Pubmed	A probability-based approach for high-throughput protein phosphorylation analysis and site localization.	ATXN2L NCOA3 NCOR1 HDAC6 LMO7 UBAP2L EPC1 NAV2 NUP153	1.56e-06	503	76	9	16964243
Pubmed	AGAP1, a novel binding partner of nitric oxide-sensitive guanylyl cyclase.	AGAP7P AGAP4 AGAP6	1.63e-06	11	76	3	15381706
Pubmed	An Oct4-centered protein interaction network in embryonic stem cells.	NCOA3 KMT2C EP400 UBP1 ARID1A MED12	1.85e-06	167	76	6	20362541
Pubmed	The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression.	ATXN2L ATXN2 UBAP2L PRRC2C TNRC6B	2.40e-06	97	76	5	37151849
Pubmed	Characterization of an exchangeable gene trap using pU-17 carrying a stop codon-beta geo cassette.	JARID2 NCOR1 TLK1 ARID2 TNRC6B AGAP7P ARID1A AGAP4 AGAP6	2.61e-06	536	76	9	15840001
Pubmed	Identification and functional characterization of transcriptional activators in human cells.	NCOA3 KMT2C EP400 UBP1 ARID2 PCLO EPC1 ARID1A	2.62e-06	398	76	8	35016035
Pubmed	Exchangeable gene trap using the Cre/mutated lox system.	JARID2 NCOR1 TLK1 ARID2 TNRC6B AGAP7P ARID1A AGAP4 AGAP6	2.70e-06	538	76	9	10512203
Pubmed	The Endosome Localized Arf-GAP AGAP1 Modulates Dendritic Spine Morphology Downstream of the Neurodevelopmental Disorder Factor Dysbindin.	AGAP7P AGAP4 AGAP6	2.82e-06	13	76	3	27713690
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	KLHL29 TOB2 EP400 UBAP2L PRRC2C TNRC6B ASXL2 ZMYM3	3.09e-06	407	76	8	12693553
Pubmed	GTP-binding protein-like domain of AGAP1 is protein binding site that allosterically regulates ArfGAP protein catalytic activity.	AGAP7P AGAP4 AGAP6	3.59e-06	14	76	3	22453919
Pubmed	Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma.	CRTC1 MAML2	4.71e-06	2	76	2	19269006
Pubmed	Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: the MD Anderson Cancer Center experience and comprehensive review of the literature.	CRTC1 MAML2	4.71e-06	2	76	2	28343305
Pubmed	ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.	HDAC6 ARID1A	4.71e-06	2	76	2	35167193
Pubmed	Altered Notch signaling resulting from expression of a WAMTP1-MAML2 gene fusion in mucoepidermoid carcinomas and benign Warthin's tumors.	CRTC1 MAML2	4.71e-06	2	76	2	14720503
Pubmed	Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma.	HDAC6 ARID1A	4.71e-06	2	76	2	30787326
Pubmed	Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens.	CRTC1 MAML2	4.71e-06	2	76	2	36675234
Pubmed	Frequent fusion of the CRTC1 and MAML2 genes in clear cell variants of cutaneous hidradenomas.	CRTC1 MAML2	4.71e-06	2	76	2	17334997
Pubmed	Role of CRTC1/MAML2 Translocation in the Prognosis and Clinical Outcomes of Mucoepidermoid Carcinoma.	CRTC1 MAML2	4.71e-06	2	76	2	26796488
Pubmed	Clear cell hidradenoma of the skin-a third tumor type with a t(11;19)--associated TORC1-MAML2 gene fusion.	CRTC1 MAML2	4.71e-06	2	76	2	15729701
Pubmed	Central mucoepidermoid carcinoma, a case report with molecular analysis of the TORC1/MAML2 gene fusion.	CRTC1 MAML2	4.71e-06	2	76	2	20625861
Pubmed	Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells.	CRTC1 MAML2	4.71e-06	2	76	2	26503699
Pubmed	CRTC1/MAML2 fusion transcript in central mucoepidermoid carcinoma of mandible--diagnostic and histogenetic implications.	CRTC1 MAML2	4.71e-06	2	76	2	21074686
Pubmed	The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma.	CRTC1 MAML2	4.71e-06	2	76	2	33830080
Pubmed	A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas.	CRTC1 MAML2	4.71e-06	2	76	2	20588178
Pubmed	Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter.	HDAC6 RUNX2	4.71e-06	2	76	2	12391164
Pubmed	Salivary mucoepidermoid carcinoma revisited.	CRTC1 MAML2	4.71e-06	2	76	2	24771140
Pubmed	Salivary mucoepidermoid carcinoma: histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features.	CRTC1 MAML2	4.71e-06	2	76	2	34657306
Pubmed	CRTC1-MAML2 fusion in mucoepidermoid carcinoma of the breast.	CRTC1 MAML2	4.71e-06	2	76	2	30380176
Pubmed	Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2.	ATXN2L ATXN2	4.71e-06	2	76	2	8896555
Pubmed	CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior.	CRTC1 MAML2	4.71e-06	2	76	2	17437281
Pubmed	Direct interactions between corepressors and coactivators permit the integration of nuclear receptor-mediated repression and activation.	NCOA3 NCOR1	4.71e-06	2	76	2	12089344
Pubmed	MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma.	CRTC1 MAML2	4.71e-06	2	76	2	16818685
Pubmed	A closer look at Warthin tumors and the t(11;19).	CRTC1 MAML2	4.71e-06	2	76	2	18206539
Pubmed	The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.	ATXN2L NCOR1 EP400 ATXN2 UBAP2L PRRC2C ARID2 ZNF207 ARID1A SAP130 NUP153	7.03e-06	954	76	11	36373674
Pubmed	An improved smaller biotin ligase for BioID proximity labeling.	NCOR1 PRRC2C TNRC6B ARID1A NUP153	7.70e-06	123	76	5	26912792
Pubmed	The TRIM9/TRIM67 neuronal interactome reveals novel activators of morphogenesis.	GGA2 PCLO TNRC6B AGAP7P AGAP4 AGAP6	8.59e-06	218	76	6	33378226
Pubmed	TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation.	NCOA3 NCOR1 KMT2C ARID2 ARID1A MED12	9.04e-06	220	76	6	35785414
Pubmed	Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.	ATXN2L NCOR1 ATXN2 UBAP2L SUPT6H UBP1 PRRC2C TNRC6B	9.55e-06	475	76	8	31040226
Pubmed	Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism.	ATXN2L NCOR1 EP400 ARID1A SAP130 MED12 NUP153	1.00e-05	341	76	7	32971831
Pubmed	Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.	KMT2C TLK1 LMO7 NAV2 TRIOBP TNRC6B	1.03e-05	225	76	6	12168954
Pubmed	Galectin-9 Is Critical for Mucosal Adaptive Immunity through the T Helper 17-IgA Axis.	LGALS9B LGALS9	1.41e-05	3	76	2	29458010
Pubmed	Identification of new human mastermind proteins defines a family that consists of positive regulators for notch signaling.	MAML2 MAML3	1.41e-05	3	76	2	12386158
Pubmed	Targeting Notch and EGFR signaling in human mucoepidermoid carcinoma.	CRTC1 MAML2	1.41e-05	3	76	2	33473104
Pubmed	Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation.	LGALS9B LGALS9	1.41e-05	3	76	2	19776007
Pubmed	Cooperative Interactions of Oligosaccharide and Peptide Moieties of a Glycopeptide Derived from IgE with Galectin-9.	LGALS9B LGALS9	1.41e-05	3	76	2	26582205
Pubmed	Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin.	LGALS9B LGALS9	1.41e-05	3	76	2	9153289
Pubmed	Galectin-9 regulates follicular helper T cells to inhibit humoral autoimmunity-induced pulmonary fibrosis.	LGALS9B LGALS9	1.41e-05	3	76	2	33316546
Pubmed	Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice.	LGALS9B LGALS9	1.41e-05	3	76	2	18974023
Pubmed	Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin.	LGALS9B LGALS9	1.41e-05	3	76	2	9038233
Pubmed	Ataxin-2-like is a regulator of stress granules and processing bodies.	ATXN2L ATXN2	1.41e-05	3	76	2	23209657
Pubmed	CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells.	CRTC1 MAML2	1.41e-05	3	76	2	29353885
Pubmed	Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion.	LGALS9B LGALS9	1.41e-05	3	76	2	23144904
Pubmed	Impaired Gal-9 Dysregulates the PBMC-Induced Th1/Th2 Imbalance in Abortion-Prone Matings.	LGALS9B LGALS9	1.41e-05	3	76	2	29651447
Pubmed	Protective effect of Galectin-9 in murine model of lung emphysema: Involvement of neutrophil migration and MMP-9 production.	LGALS9B LGALS9	1.41e-05	3	76	2	28704475
Pubmed	Uncommon somatic mutations in metastatic NUT midline carcinoma.	KMT2C DCC	1.41e-05	3	76	2	28967088
Pubmed	The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity.	LGALS9B LGALS9	1.41e-05	3	76	2	21146220
Pubmed	Cutaneous hidradenoma: a study of 21 neoplasms revealing neither correlation between the cellular composition and CRTC1-MAML2 fusions nor presence of CRTC3-MAML2 fusions.	CRTC1 MAML2	1.41e-05	3	76	2	27402217
Pubmed	Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage.	HDAC6 RUNX2	1.41e-05	3	76	2	23618908
Pubmed	Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes.	ARID2 ARID1A	1.41e-05	3	76	2	26716708
Pubmed	Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis.	LGALS9B LGALS9	1.41e-05	3	76	2	23836896
Pubmed	Sequence and mapping of galectin-5, a beta-galactoside-binding lectin, found in rat erythrocytes.	LGALS9B LGALS9	1.41e-05	3	76	2	7890611
Pubmed	Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner.	LGALS9B LGALS9	1.41e-05	3	76	2	22341088
Pubmed	Regulation of M1‑type and M2‑type macrophage polarization in RAW264.7 cells by Galectin‑9.	LGALS9B LGALS9	1.41e-05	3	76	2	28990062
Pubmed	Galectin-9 Is a Novel Regulator of Epithelial Restitution.	LGALS9B LGALS9	1.41e-05	3	76	2	32380082
Pubmed	Galectin-9-mediated protection from allo-specific T cells as a mechanism of immune privilege of corneal allografts.	LGALS9B LGALS9	1.41e-05	3	76	2	23667648
Pubmed	Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices.	LGALS9B LGALS9	1.41e-05	3	76	2	18579572
Pubmed	Regulatory T Cell-Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9.	LGALS9B LGALS9	1.41e-05	3	76	2	28877989
Pubmed	Galectin-9 ameliorates immune complex-induced arthritis by regulating Fc gamma R expression on macrophages.	LGALS9B LGALS9	1.41e-05	3	76	2	19800850
Pubmed	The effect of Toxoplasma gondii infection on galectin-9 expression in decidual macrophages contributing to dysfunction of decidual NK cells during pregnancy.	LGALS9B LGALS9	1.41e-05	3	76	2	38987795
Pubmed	ARID1A-mutated ovarian cancers depend on HDAC6 activity.	HDAC6 ARID1A	1.41e-05	3	76	2	28737768
Pubmed	Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition.	LGALS9B LGALS9	1.41e-05	3	76	2	16990264
Pubmed	Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue.	LGALS9B LGALS9	1.41e-05	3	76	2	18005988
Pubmed	Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3.	LGALS9B LGALS9	1.41e-05	3	76	2	23585851
Pubmed	Galectin-9 ameliorates anti-GBM glomerulonephritis by inhibiting Th1 and Th17 immune responses in mice.	LGALS9B LGALS9	1.41e-05	3	76	2	24477688
Interaction	CRX interactions	SMAP1 NCOA3 KMT2C EP400 NFIA ARID2 EPC1 PROSER1 ASXL2 ARID1A TFG MED12 ZMYM3	1.12e-11	254	76	13	int:CRX
Interaction	SOX9 interactions	NCOA3 KMT2C EP400 NFIA ARID2 RUNX2 HERC1 ARID1A MED12	1.04e-10	97	76	9	int:SOX9
Interaction	HNF1B interactions	NCOA3 NCOR1 KMT2C EP400 NFIA ARID2 EPC1 PROSER1 ASXL2 ARID1A SAP130	1.31e-10	190	76	11	int:HNF1B
Interaction	HNF4A interactions	NCOA3 NCOR1 KMT2C EP400 NFIA ARID2 EPC1 ASXL2 ARID1A SAP130 ZMYM3 SMAD4	4.68e-10	275	76	12	int:HNF4A
Interaction	PAX6 interactions	NCOA3 NCOR1 KMT2C TLK1 EP400 NFIA ARID2 ASXL2 ARID1A SAP130 ZMYM3 SMAD4	1.17e-08	366	76	12	int:PAX6
Interaction	EGR2 interactions	NCOA3 NCOR1 KMT2C EP400 NFIA ARID2 EPC1 PROSER1 ARID1A	1.62e-08	171	76	9	int:EGR2
Interaction	KLF5 interactions	NCOA3 NCOR1 KMT2C EP400 NFIA ARID2 EPC1 ARID1A SMAD4	5.03e-08	195	76	9	int:KLF5
Interaction	NUP35 interactions	NCOA3 NCOR1 KMT2C ATXN2 PRRC2C TNRC6B ZNF207 ARID1A TFG SAP130 MAML3 NUP153	5.92e-08	424	76	12	int:NUP35
Interaction	GATA2 interactions	NCOA3 NCOR1 KMT2C NFIA ARID2 ASXL2 ARID1A SAP130 SMAD4	5.99e-08	199	76	9	int:GATA2
Interaction	FEV interactions	NCOA3 NCOR1 KMT2C EP400 NFIA ARID2 ASXL2 ARID1A ZMYM3	7.11e-08	203	76	9	int:FEV
Interaction	SP7 interactions	NCOA3 NCOR1 KMT2C EP400 NFIA ARID2 EPC1 PROSER1 ARID1A SAP130	2.09e-07	304	76	10	int:SP7
Interaction	ETS1 interactions	NCOA3 NCOR1 GGA2 EP400 ARID2 RUNX2 ARID1A	3.66e-07	121	76	7	int:ETS1
Interaction	NUP43 interactions	NCOR1 EP400 NFIA SUPT6H PRRC2C ARID2 EPC1 TNRC6B ASXL2 ARID1A MED12 ZMYM3 NUP153	5.50e-07	625	76	13	int:NUP43
Interaction	PAX9 interactions	NCOA3 NCOR1 KMT2C NFIA PROSER1 ARID1A SAP130	5.97e-07	130	76	7	int:PAX9
Interaction	CEBPA interactions	ATXN2L NCOA3 NCOR1 KMT2C TLK1 EP400 ATXN2 PRRC2C ARID2 ZNF207 ASXL2 RUNX2 ARID1A SAP130 MED12 ZMYM3 NUP153 SMAD4	6.18e-07	1245	76	18	int:CEBPA
Interaction	SOX10 interactions	NCOA3 NCOR1 NFIA ARID2 PROSER1 ARID1A	1.30e-06	92	76	6	int:SOX10
Interaction	SOX17 interactions	NCOA3 NCOR1 KMT2C NFIA ARID2 ARID1A	1.57e-06	95	76	6	int:SOX17
Interaction	NANOG interactions	JARID2 ATXN2L NCOR1 KMT2C EP400 SUPT6H MUC16 ARID1A SAP130 MED12 SMAD4	1.81e-06	481	76	11	int:NANOG
Interaction	NFIX interactions	NCOR1 KMT2C EP400 NFIA ARID2 ARID1A SAP130 SMAD4	2.24e-06	227	76	8	int:NFIX
Interaction	KLF3 interactions	NCOR1 EP400 NFIA ARID2 EPC1 ARID1A SAP130 ZMYM3	2.31e-06	228	76	8	int:KLF3
Interaction	FOS interactions	NCOA3 NCOR1 KMT2C EP400 NFIA LMO7 ARID2 RUNX2 ARID1A	2.61e-06	312	76	9	int:FOS
Interaction	AR interactions	NCOA3 NCOR1 KMT2C EP400 NFIA UBAP2L ARID2 EPC1 PRKD1 RUNX2 DCC ARID1A SAP130 MED12 SMAD4	3.67e-06	992	76	15	int:AR
Interaction	EN1 interactions	NCOR1 KMT2C EP400 NFIA ASXL2 SAP130	3.69e-06	110	76	6	int:EN1
Interaction	PAX8 interactions	NCOA3 NCOR1 KMT2C NFIA PROSER1 ARID1A	3.89e-06	111	76	6	int:PAX8
Interaction	PIGF interactions	ANKRD13D HDAC6 SUPT6H GPR152	4.13e-06	29	76	4	int:PIGF
Interaction	TBR1 interactions	NCOA3 NCOR1 KMT2C NFIA PROSER1 ARID1A	4.32e-06	113	76	6	int:TBR1
Interaction	TLX1 interactions	NCOA3 NCOR1 KMT2C NFIA ASXL2 ARID1A SAP130	4.36e-06	175	76	7	int:TLX1
Interaction	TBXT interactions	NCOA3 NCOR1 KMT2C NFIA ARID1A SAP130	5.03e-06	116	76	6	int:TBXT
Interaction	PPIA interactions	SMAP1 HDAC6 EP400 ARID2 KPRP TNRC6B ZNF207 ASXL2 ARID1A TFG SAP130 MED12 NUP153 LGALS9	5.05e-06	888	76	14	int:PPIA
Interaction	GCM1 interactions	NCOA3 NCOR1 KMT2C NFIA ARID1A	5.78e-06	68	76	5	int:GCM1
Interaction	ALG13 interactions	NCOA3 NCOR1 ATXN2 UBAP2L PRRC2C TNRC6B ARID1A	5.85e-06	183	76	7	int:ALG13
Interaction	LHX2 interactions	NCOR1 KMT2C TLK1 EP400 NFIA ARID2 ARID1A	5.85e-06	183	76	7	int:LHX2
Interaction	SMAP2 interactions	SMAP1 GGA2 TUT4 ATXN2 UBAP2L PRRC2C TNRC6B	7.23e-06	189	76	7	int:SMAP2
Interaction	PAX7 interactions	NCOA3 NCOR1 KMT2C NFIA ARID1A SAP130	7.39e-06	124	76	6	int:PAX7
Interaction	FXR1 interactions	ATXN2L NCOR1 TUT4 ATXN2 UBAP2L UBP1 PRRC2C TRIOBP TNRC6B PRKD1 CEP126 NUP153	8.36e-06	679	76	12	int:FXR1
Interaction	MYOD1 interactions	NCOA3 NCOR1 KMT2C EP400 NFIA ARID1A SMAD4	8.57e-06	194	76	7	int:MYOD1
Interaction	R3HDM2 interactions	TUT4 ATXN2 UBAP2L PRRC2C TNRC6B TFG	9.27e-06	129	76	6	int:R3HDM2
Interaction	JUN interactions	ATXN2L NCOA3 NCOR1 KMT2C GGA2 LMO7 PRKD1 BEND4 RUNX2 SMAD4	1.04e-05	470	76	10	int:JUN
Interaction	TLE3 interactions	NCOA3 NCOR1 NFIA ARID2 ZNF207 PROSER1 ASXL2 ARID1A SAP130	1.18e-05	376	76	9	int:TLE3
Interaction	KLF15 interactions	NCOA3 NCOR1 KMT2C EP400 PRRC2C ARID2 EPC1 SAP130	1.35e-05	290	76	8	int:KLF15
Interaction	TLX3 interactions	NCOA3 NCOR1 KMT2C NFIA ARID2 PROSER1 ARID1A SMAD4	1.38e-05	291	76	8	int:TLX3
Interaction	IRF4 interactions	NCOA3 KMT2C NFIA ARID2 ARID1A	1.73e-05	85	76	5	int:IRF4
Interaction	FHL2 interactions	ATXN2L NCOR1 EP400 PRRC2C KPRP ASXL2 RUNX2 SAP130 SMAD4	1.78e-05	396	76	9	int:FHL2
Interaction	DAZL interactions	ATXN2L TUT4 ATXN2 UBAP2L PRRC2C TNRC6B	1.81e-05	145	76	6	int:DAZL
Interaction	NID2 interactions	ANKRD13D KPRP TFG MAML3 LGALS9	1.83e-05	86	76	5	int:NID2
Interaction	MEX3B interactions	ATXN2L TUT4 ATXN2 UBAP2L PRRC2C TNRC6B SMAD4	2.05e-05	222	76	7	int:MEX3B
Interaction	FOXI1 interactions	NCOA3 KMT2C NFIA ASXL2 ARID1A	2.54e-05	92	76	5	int:FOXI1
Interaction	SOX6 interactions	NCOA3 NCOR1 NFIA PRRC2C PROSER1 SAP130	2.83e-05	157	76	6	int:SOX6
Interaction	WWTR1 interactions	ATXN2L NCOR1 EP400 LMO7 PRRC2C ARID2 TNRC6B RUNX2 ARID1A	2.93e-05	422	76	9	int:WWTR1
Interaction	KLF8 interactions	NCOA3 EP400 NFIA PRRC2C ARID2 EPC1 SAP130 ZMYM3	3.33e-05	329	76	8	int:KLF8
Interaction	LHX4 interactions	NCOR1 KMT2C NFIA ARID2 ARID1A SMAD4	3.87e-05	166	76	6	int:LHX4
Interaction	YAP1 interactions	ATXN2L NCOR1 KMT2C UBAP2L PRRC2C ARID2 TRIOBP TNRC6B NDFIP2 PRKD1 RUNX2 ARID1A SAP130 MED12	5.24e-05	1095	76	14	int:YAP1
Interaction	TEAD1 interactions	NCOR1 KMT2C NFIA ARID2 ASXL2 ARID1A	5.37e-05	176	76	6	int:TEAD1
Interaction	NOTCH4 interactions	MAML2 MAML3 SMAD4	6.53e-05	21	76	3	int:NOTCH4
Interaction	LHX3 interactions	NCOR1 KMT2C NFIA ARID2 DCC ARID1A	7.08e-05	185	76	6	int:LHX3
Interaction	SMAD2 interactions	NCOA3 KMT2C MTMR4 NFIA RUNX2 ARID1A NUP153 SMAD4	1.00e-04	385	76	8	int:SMAD2
Interaction	MEN1 interactions	ATXN2L NCOR1 KMT2C EP400 LMO7 ARID2 RUNX2 ARID1A SAP130 MED12 ZMYM3 NUP153 SMAD4	1.13e-04	1029	76	13	int:MEN1
Interaction	ELF1 interactions	EP400 NFIA ARID2 EPC1 ASXL2	1.14e-04	126	76	5	int:ELF1
Interaction	RBM47 interactions	TUT4 ATXN2 LMO7 UBAP2L PRRC2C TNRC6B	1.21e-04	204	76	6	int:RBM47
Interaction	CNOT3 interactions	ATXN2L TOB2 UBAP2L PRRC2C EPC1 TNRC6B	1.31e-04	207	76	6	int:CNOT3
Interaction	RBMS1 interactions	ATXN2L TUT4 ATXN2 UBAP2L PRRC2C TNRC6B	1.31e-04	207	76	6	int:RBMS1
Interaction	SNRNP40 interactions	NCOR1 TLK1 EP400 NFIA SUPT6H ARID2 KPRP ZNF207 ARID1A MED12	1.35e-04	637	76	10	int:SNRNP40
Interaction	EWSR1 interactions	JARID2 NCOA3 NCOR1 HDAC6 UBAP2L UBP1 PCLO ZNF207 PROSER1 ARID1A TFG SMAD4	1.38e-04	906	76	12	int:EWSR1
Interaction	UNK interactions	ATXN2L ATXN2 UBAP2L PRRC2C TNRC6B HERC1 ARID1A TFG	1.49e-04	408	76	8	int:UNK
Interaction	PKP3 interactions	MTMR4 HDAC6 PRKD1 MED12 SMAD4	1.64e-04	136	76	5	int:PKP3
Interaction	PML interactions	SMAP1 NCOR1 TLK1 HDAC6 EP400 LMO7 UBAP2L TNRC6B ZNF207 RUNX2 SAP130 ZMYM3	1.82e-04	933	76	12	int:PML
Interaction	ERG interactions	NCOA3 NCOR1 KMT2C NFIA ASXL2 ARID1A	1.97e-04	223	76	6	int:ERG
Interaction	NFIB interactions	NCOA3 NCOR1 KMT2C NFIA ARID1A	2.00e-04	142	76	5	int:NFIB
Interaction	SMG7 interactions	NCOA3 NCOR1 MTMR4 ATXN2 UBAP2L TNRC6B ARID1A	2.00e-04	319	76	7	int:SMG7
Interaction	BRCA1 interactions	ATXN2L NCOA3 UBAP2L DTNA SUPT6H TNRC6B ZNF207 HERC1 ARID1A TFG MED12 ZMYM3 NUP153 SMAD4	2.11e-04	1249	76	14	int:BRCA1
Interaction	FXR2 interactions	TUT4 HDAC6 ATXN2 UBAP2L PRRC2C TRIOBP TNRC6B PRKD1	2.14e-04	430	76	8	int:FXR2
Interaction	SOX7 interactions	NCOA3 KMT2C ARID2 ARID1A	2.61e-04	82	76	4	int:SOX7
Interaction	PHB1 interactions	ATXN2L NCOR1 HDAC6 ATXN2 UBAP2L DTNA PRRC2C TNRC6B SCAMP2 ARID1A C2orf78 TFG LGALS9	2.68e-04	1123	76	13	int:PHB1
Interaction	NR0B2 interactions	NCOA3 HDAC6 RUNX2 SMAD4	2.74e-04	83	76	4	int:NR0B2
Interaction	SMAD3 interactions	ATXN2L NCOA3 NFIA RUNX2 ARID1A SAP130 NUP153 SMAD4	2.77e-04	447	76	8	int:SMAD3
Interaction	TFAP4 interactions	NFIA UBP1 ARID2 ARID1A SAP130	2.83e-04	153	76	5	int:TFAP4
Interaction	WWP2 interactions	ATXN2L SMAP1 LGALS9B ATXN2 UBAP2L SUPT6H UBP1 PRRC2C NDFIP2 RUNX2 ARID1A	2.98e-04	840	76	11	int:WWP2
Interaction	NUP50 interactions	NCOR1 HDAC6 SUPT6H ARID2 ARID1A SAP130 NUP153	3.00e-04	341	76	7	int:NUP50
Interaction	RUVBL1 interactions	HDAC6 EP400 SUPT6H EPC1 ASXL2 CEP126 ARID1A MED12 LGALS9	3.06e-04	575	76	9	int:RUVBL1
Interaction	ELF2 interactions	EP400 NFIA EPC1 ASXL2 SAP130	3.09e-04	156	76	5	int:ELF2
Interaction	CPEB4 interactions	TUT4 ATXN2 UBAP2L PRRC2C TNRC6B	3.09e-04	156	76	5	int:CPEB4
Interaction	CHEK1 interactions	TLK1 MTMR4 HDAC6 TNRC6B ARID1A SMAD4	3.26e-04	245	76	6	int:CHEK1
Interaction	ASF1A interactions	NCOR1 TLK1 EP400 ARID2 ARID1A SAP130	3.56e-04	249	76	6	int:ASF1A
Interaction	SOX5 interactions	NCOR1 NFIA PRRC2C PROSER1 SAP130	3.68e-04	162	76	5	int:SOX5
Interaction	DCP1A interactions	ATXN2L TUT4 ATXN2 TNRC6B SMAD4	4.11e-04	166	76	5	int:DCP1A
Interaction	CREBBP interactions	NCOA3 NCOR1 NFIA SUPT6H CRTC1 MAML2 RUNX2 ARID1A SMAD4	4.12e-04	599	76	9	int:CREBBP
Interaction	CNOT6L interactions	TOB2 UBAP2L TNRC6B DCC	4.23e-04	93	76	4	int:CNOT6L
Interaction	LSM14A interactions	ATXN2L TUT4 ATXN2 UBAP2L PRRC2C TNRC6B	4.47e-04	260	76	6	int:LSM14A
Interaction	KLF6 interactions	CELSR2 EP400 ARID2 EPC1	4.59e-04	95	76	4	int:KLF6
Interaction	ESRRB interactions	NCOA3 KMT2C EP400 UBP1 ARID1A MED12	4.66e-04	262	76	6	int:ESRRB
Interaction	ATXN1 interactions	ATXN2L NCOR1 GGA2 NFIA ATXN2 UBAP2L PRRC2C NDFIP2 ZNF207 SCAMP2 ARID1A SAP130	4.84e-04	1039	76	12	int:ATXN1
Interaction	GLI3 interactions	HDAC6 TNRC6B MED12 SMAD4	5.16e-04	98	76	4	int:GLI3
Interaction	TFCP2L1 interactions	EP400 UBP1 ARID1A SMAD4	5.36e-04	99	76	4	int:TFCP2L1
Interaction	NFYC interactions	SMAP1 USF3 EP400 ARID2 ASXL2	5.51e-04	177	76	5	int:NFYC
Interaction	ARID1B interactions	NCOA3 NFIA ARID2 ARID1A SMAD4	5.51e-04	177	76	5	int:ARID1B
Interaction	SIRT6 interactions	ATXN2L CELSR2 EP400 UBAP2L SUPT6H ARID2 ARID1A MED12 NUP153	5.80e-04	628	76	9	int:SIRT6
Interaction	ZFP36 interactions	TUT4 ATXN2 UBAP2L PRRC2C TNRC6B	6.10e-04	181	76	5	int:ZFP36
Interaction	HEMGN interactions	SUPT6H DCC SMAD4	6.11e-04	44	76	3	int:HEMGN
Interaction	FOXR1 interactions	HDAC6 EP400 EPC1	6.11e-04	44	76	3	int:FOXR1
Interaction	H2AC4 interactions	KMT2C USF3 HDAC6 EP400 SUPT6H ARID2 ARID1A ZMYM3	6.31e-04	506	76	8	int:H2AC4
GeneFamily	Ataxins\|Trinucleotide repeat containing	NCOA3 EP400 ATXN2 TNRC6B MAML3 MED12	4.32e-11	25	48	6	775
GeneFamily	ArfGAPs	SMAP1 AGAP7P AGAP4 AGAP6	1.69e-06	33	48	4	395
GeneFamily	AT-rich interaction domain containing	JARID2 ARID2 ARID1A	7.81e-06	15	48	3	418
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	TRIOBP PRKD1 AGAP7P AGAP4 AGAP6	2.10e-04	206	48	5	682
GeneFamily	Synaptotagmin like tandem C2 proteins	TC2N SYTL3	3.06e-04	10	48	2	822
GeneFamily	Galectins	LGALS9B LGALS9	7.09e-04	15	48	2	629
GeneFamily	X-linked mental retardation\|Rho GTPase activating proteins\|BAR-PH domain containing	AGAP4 AGAP6	9.15e-04	17	48	2	1291
GeneFamily	Ankyrin repeat domain containing	ANKRD13D AGAP7P AGAP4 AGAP6	3.84e-03	242	48	4	403
GeneFamily	GATA zinc finger domain containing\|Myb/SANT domain containing	NCOR1 EP400	8.73e-03	53	48	2	532
GeneFamily	G protein-coupled receptors, Class A orphans	GPR34 GPR152	1.82e-02	78	48	2	262
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	JARID2 ATXN2L NCOA3 NCOR1 KMT2C TLK1 GGA2 TUT4 TC2N EP400 SYTL3 ARID2 EPC1 TNRC6B ASXL2 RUNX2 HERC1 ARID1A NUP153	2.69e-08	1492	75	19	M40023
Coexpression	GSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP	NCOR1 KMT2C TUT4 CELSR2 PRRC2C HERC1 ARID1A	8.58e-07	180	75	7	M8239
Coexpression	KARLSSON_TGFB1_TARGETS_DN	NFIA SUPT6H TNRC6B BEND4 AGAP7P AGAP4 AGAP6	2.32e-06	209	75	7	MM1058
Coexpression	TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_EPITHELIAL_CELL_AGEING	ATXN2L SMAP1 TOB2 TLK1 GPR34 TNRC6B MAML2 SAP130 NUP153 SMAD4	4.94e-06	568	75	10	MM3824
Coexpression	SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN	NCOR1 KMT2C TOB2 TLK1 NFIA UBAP2L PRRC2C TRIOBP TNRC6B	7.43e-06	467	75	9	M1347
Coexpression	SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN	NCOR1 KMT2C TOB2 TLK1 NFIA UBAP2L PRRC2C TRIOBP TNRC6B	9.89e-06	484	75	9	MM999
Coexpression	NAKAYA_MYELOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_DN	MTMR4 TUT4 EP400 DTNA PRKD1 NUP153 SMAD4	1.16e-05	267	75	7	M41130
Coexpression	GSE40273_GATA1_KO_VS_WT_TREG_DN	NCOA3 KMT2C PRRC2C EPC1 PROSER1 MED12	2.38e-05	200	75	6	M9133
Coexpression	TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN	ANKRD13D NCOR1 TUT4 ARID2 ASXL2	3.91e-05	132	75	5	M15410
Coexpression	THUM_SYSTOLIC_HEART_FAILURE_DN	NCOR1 TOB2 LMO7 ZNF207 SMAD4 C16orf46	4.83e-05	227	75	6	M18441
Coexpression	TAYLOR_METHYLATED_IN_ACUTE_LYMPHOBLASTIC_LEUKEMIA	GTPBP2 TUT4 NFIA MAML3	7.51e-05	78	75	4	M2438
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN	KLHL29 NCOR1 COL6A3 MTMR4 LGALS9B DTNA PRRC2C NAV2 TNRC6B SCAMP2 DCC LGALS9	7.84e-05	1124	75	12	MM1070
Coexpression	RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN	NCOR1 TOB2 NFIA ATXN2 DTNA ARID2 TNRC6B ZNF207 HERC1 SMAD4	9.84e-05	807	75	10	M16651
Coexpression	SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX4_DN	TOB2 NFIA TNRC6B	1.15e-04	33	75	3	M1359
Coexpression	UEDA_PERIFERAL_CLOCK	LGALS9B ATXN2 LMO7 UBAP2L LGALS9	1.56e-04	177	75	5	MM1145
Coexpression	SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX4_DN	TOB2 NFIA TNRC6B	1.63e-04	37	75	3	MM570
Coexpression	THEODOROU_MAMMARY_TUMORIGENESIS	AGAP7P AGAP4 AGAP6	1.63e-04	37	75	3	MM1121
Coexpression	GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_UP	JARID2 LGALS9B LMO7 PRRC2C LGALS9	2.07e-04	188	75	5	MM983
Coexpression	GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN	MTMR4 EP400 SLC15A1 NAV2 TRIOBP	2.45e-04	195	75	5	M10007
Coexpression	GSE29617_CTRL_VS_DAY3_TIV_FLU_VACCINE_PBMC_2008_UP	JARID2 PRRC2C MAML2 NUP153 SMAD4	2.51e-04	196	75	5	M4928
Coexpression	GSE26290_CTRL_VS_AKT_INHIBITOR_TREATED_ANTI_CD3_AND_IL2_STIM_CD8_TCELL_DN	JARID2 NCOA3 TLK1 NDFIP2 MAML3	2.57e-04	197	75	5	M8133
Coexpression	BUSSLINGER_DUODENAL_IMMUNE_CELLS	ANKRD13D ATXN2L SYTL3 PRRC2C ARID2 TNRC6B ZNF207 ASXL2 HERC1 ARID1A	2.63e-04	911	75	10	M40038
Coexpression	GSE27786_LSK_VS_NKTCELL_DN	ANKRD13D JARID2 GTPBP2 ASXL2 MED12	2.63e-04	198	75	5	M4756
Coexpression	GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_DN	AGAP7P AGAP4 AGAP6	2.74e-04	44	75	3	MM485
Coexpression	GSE31082_DN_VS_CD4_SP_THYMOCYTE_DN	JARID2 NCOA3 GTPBP2 TUT4 TRIOBP	2.75e-04	200	75	5	M5059
Coexpression	GSE13493_DP_VS_CD4INTCD8POS_THYMOCYTE_UP	USF3 CELSR2 UBP1 NAV2 NDFIP2	2.75e-04	200	75	5	M3312
Coexpression	GSE12001_MIR223_KO_VS_WT_NEUTROPHIL_DN	SMAP1 TOB2 UBP1 EPC1 ZMYM3	2.75e-04	200	75	5	M391
Coexpression	GSE15324_NAIVE_VS_ACTIVATED_CD8_TCELL_UP	KMT2C NFIA GPR34 DTNA CEP126	2.75e-04	200	75	5	M3523
Coexpression	GSE32986_UNSTIM_VS_GMCSF_AND_CURDLAN_LOWDOSE_STIM_DC_DN	NFIA UBAP2L EPC1 ASXL2 RUNX2	2.75e-04	200	75	5	M8620
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN	KLHL29 NCOR1 COL6A3 MTMR4 DTNA PRRC2C NAV2 TNRC6B SCAMP2 DCC LGALS9	2.87e-04	1102	75	11	M2369
Coexpression	RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_UP	NCOA3 CELSR2 SLC15A1 NFIA TNRC6B	3.02e-04	204	75	5	M1844
Coexpression	HOFMANN_MYELODYSPLASTIC_SYNDROM_HIGH_RISK_UP	CELSR2 ZMYM3	3.58e-04	10	75	2	M14215
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN	JARID2 NCOA3 TLK1 TUT4 ATXN2 PRRC2C NUP153	3.76e-04	466	75	7	M13522
CoexpressionAtlas	DevelopingGonad_e12.5_ovary_emap-28876_top-relative-expression-ranked_1000	NCOA3 GGA2 NFIA ATXN2 UBAP2L PRRC2C NAV2 ZNF207 PRKD1 ASXL2 HERC1 ARID1A NUP153	3.69e-06	804	74	13	gudmap_developingGonad_e12.5_ovary_1000
CoexpressionAtlas	DevelopingGonad_e14.5_ epididymis_emap-29141_k-means-cluster#3_top-relative-expression-ranked_1000	NCOA3 KMT2C TLK1 GGA2 ATXN2 NAV2 ZNF207 HERC1	5.14e-06	275	74	8	gudmap_developingGonad_e14.5_ epididymis_1000_k3
CoexpressionAtlas	FacebaseRNAseq_e10.5_Medial Nasal Eminence_top-relative-expression-ranked_1000	SMAP1 COL6A3 NRSN2 TUT4 CELSR2 NFIA UBP1 PCLO KPRP CEP126 ARID1A RTN4RL2 MAML3 LGALS9	6.15e-06	979	74	14	Facebase_RNAseq_e10.5_Medial Nasal Eminence_1000
CoexpressionAtlas	DevelopingGonad_e14.5_ epididymis_emap-29141_top-relative-expression-ranked_1000	NCOA3 KMT2C TLK1 GGA2 TUT4 ADGRG2 NFIA ATXN2 PRRC2C NAV2 ZNF207 HERC1	1.95e-05	801	74	12	gudmap_developingGonad_e14.5_ epididymis_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Medial Nasal Eminence_top-relative-expression-ranked_1000_k-means-cluster#4	SMAP1 COL6A3 TUT4 UBP1 CEP126 ARID1A MAML3	8.05e-05	298	74	7	Facebase_RNAseq_e10.5_Medial Nasal Eminence_1000_K4
CoexpressionAtlas	DevelopingGonad_e16.5_epididymis_emap-29702_top-relative-expression-ranked_500	NCOA3 ADGRG2 NFIA ATXN2 PRRC2C NAV2 ZNF207 HERC1	8.35e-05	406	74	8	gudmap_developingGonad_e16.5_epididymis_500
CoexpressionAtlas	DevelopingGonad_e16.5_ovary_emap-9563_top-relative-expression-ranked_1000	KMT2C TC2N ADGRG2 NFIA ATXN2 PRRC2C NAV2 ZNF207 PRKD1 HERC1 LGALS9	9.18e-05	795	74	11	gudmap_developingGonad_e16.5_ovary_1000
CoexpressionAtlas	DevelopingGonad_e18.5_epididymis_emap-13166_top-relative-expression-ranked_1000	NCOA3 KMT2C GGA2 ADGRG2 NFIA ATXN2 PRRC2C NAV2 ZNF207 HERC1 LGALS9	9.60e-05	799	74	11	gudmap_developingGonad_e18.5_epididymis_1000
CoexpressionAtlas	DevelopingGonad_e12.5_epididymis_emap-29139_top-relative-expression-ranked_1000	NCOA3 NFIA ATXN2 UBAP2L DTNA PRRC2C NAV2 ZNF207 HERC1 ARID1A NUP153	1.04e-04	806	74	11	gudmap_developingGonad_e12.5_epididymis_1000
CoexpressionAtlas	alpha beta T cells, T.8Nve.PP, TCRb+ CD8+ CD44low CD62L high, Peyer's Patch, avg-1	KMT2C TUT4 SYTL3 PRRC2C MAML2 HERC1 MED12	1.69e-04	336	74	7	GSM538413_500
CoexpressionAtlas	DevelopingGonad_e12.5_epididymis_emap-29139_k-means-cluster#5_top-relative-expression-ranked_500	ATXN2 PRRC2C NAV2 ZNF207 HERC1	1.79e-04	150	74	5	gudmap_developingGonad_e12.5_epididymis_k5_500
ToppCell	LA-02._Fibroblast_II\|World / Chamber and Cluster_Paper	KLHL29 COL6A3 TC2N NFIA NAV2 MAML2 CEP126	4.38e-08	195	76	7	a78b605b49acd8c9d68716266ca269dafcd910b9
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NCOR1 KMT2C HDAC6 PRRC2C PCLO NAV2 HERC1	4.38e-08	195	76	7	3e519cffa6144a62b06124642a14c9ff39b76554
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NCOR1 KMT2C HDAC6 PRRC2C PCLO NAV2 HERC1	4.38e-08	195	76	7	7796ea9247f4c63762f0de8490fed08b9717fa23
ToppCell	3'_v3-Lung-Lymphocytic_T_CD4-T_CD4/CD8\|Lung / Manually curated celltypes from each tissue	TUT4 TC2N SYTL3 PRRC2C GPR152 TNRC6B	2.33e-07	151	76	6	999c11d19b61d6b130ad5e623afa83cbdfe13cdd
ToppCell	TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-5\|TCGA-Ovary / Sample_Type by Project: Shred V9	USF3 UBAP2L EPC1 ARID1A MAML3 C16orf46	4.07e-07	166	76	6	32d2eaf8a5d03881bf74d680825af2d5110b082d
ToppCell	T_cells-Tph_and_Tfh\|T_cells / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	JARID2 COL6A3 LGALS9B NDFIP2 TASL LGALS9	5.73e-07	176	76	6	56c055488e34605d32562571a2fee621b47c9441
ToppCell	RA-01._Fibroblast_I\|World / Chamber and Cluster_Paper	COL6A3 TC2N NFIA NAV2 PRKD1 MAML2	6.75e-07	181	76	6	2b6ddeb53a79a658e2ba78527ff48c155b20daa6
ToppCell	LA-01._Fibroblast_I\|World / Chamber and Cluster_Paper	COL6A3 TC2N NFIA NAV2 MAML2 CEP126	8.17e-07	187	76	6	4ea486991f66c29728d127171a07b81404ec0b78
ToppCell	human_hepatoblastoma-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	JARID2 TUT4 ATXN2 ARID2 TNRC6B PRKD1	9.53e-07	192	76	6	916fbec1c7ab7969bda711886ac88e877e30c280
ToppCell	10x5'-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8\|lymph-node_spleen / Manually curated celltypes from each tissue	KMT2C COL6A3 TC2N SYTL3 MAML2 HERC1	9.53e-07	192	76	6	47646d7e4990be85072987f92bf18d52f8da752e
ToppCell	human_hepatoblastoma\|World / Sample and Cell Type and Tumor Cluster (all cells)	JARID2 TUT4 ATXN2 PRRC2C ARID2 TNRC6B	9.82e-07	193	76	6	e6a688bc834f845ff64dae1be64f073eec5091a1
ToppCell	RA-02._Fibroblast_II\|RA / Chamber and Cluster_Paper	COL6A3 TC2N NFIA NAV2 PRKD1 MAML2	1.04e-06	195	76	6	6a02ebbeb3199447ddce64d92d8809436e040eba
ToppCell	RA-02._Fibroblast_II\|World / Chamber and Cluster_Paper	COL6A3 TC2N NFIA NAV2 PRKD1 MAML2	1.07e-06	196	76	6	e8cbda03837f1f26470a9d93aa7fdaa04e08e38a
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	KMT2C NFIA TNRC6B MAML2 HERC1 MAML3	1.17e-06	199	76	6	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	RA-01._Fibroblast_I\|RA / Chamber and Cluster_Paper	COL6A3 TC2N NFIA NAV2 MAML2	1.05e-05	169	76	5	6373562ab3b1765060212a6a53d6543e7e942e80
ToppCell	pdx\|World / Sample and Cell Type and Tumor Cluster (all cells)	JARID2 NCOA3 ATXN2 ARID1A MAML3	1.67e-05	186	76	5	de8e538c8767d41b8a52f5e58ba1affd4e7244c4
ToppCell	pdx-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	JARID2 NCOA3 ATXN2 ARID1A MAML3	1.67e-05	186	76	5	0b88a87158a9ca8de3bf40a4ff1687150707a5f0
ToppCell	Control-Fibroblasts-Alveolar_FB\|Control / group, cell type (main and fine annotations)	COL6A3 DTNA NAV2 PRKD1 DCC	1.71e-05	187	76	5	92d468dde81125d51daf7abd4703741abe1ab91c
ToppCell	10x_3'_v3-thymus_(10x_3'_v3)-lymphocytic-T_lymphocytic_-_developing-thymocyte\|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	COL6A3 LMO7 SYTL3 EPC1 MAML3	1.75e-05	188	76	5	bcfc426b60d8e5a23a2360bfb68b32868fec9fbf
ToppCell	Control-Myeloid-cDC2\|World / Disease state, Lineage and Cell class	JARID2 SYTL3 RUNX2 TASL MAML3	1.89e-05	191	76	5	11dfd8f38beb294f42710cfbd355cb089e1023c0
ToppCell	LV-02._Fibroblast_II\|LV / Chamber and Cluster_Paper	COL6A3 TC2N NFIA MAML2 CEP126	2.04e-05	194	76	5	014d2feb5db2a6a35ef759761a41e466e108c3c1
ToppCell	LA-02._Fibroblast_II\|LA / Chamber and Cluster_Paper	COL6A3 TC2N NFIA NAV2 MAML2	2.04e-05	194	76	5	234d1494c114cce77c619708bbcd8d5ce805f19b
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	TLK1 TUT4 TC2N PRRC2C EPC1	2.20e-05	197	76	5	ef2d1f56acd0be43e69bba7f73f6909ba87f1cb3
ToppCell	severe-low-quality_cells\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	KMT2C TC2N PRRC2C ZNF207 HERC1	2.20e-05	197	76	5	57ebd552f10d6278623b52a3d484d4b91ae1d028
ToppCell	(03)_KRT6B+-(2)_GFP_FOXI1\|(03)_KRT6B+ / shred by cell type by condition	NCOR1 LMO7 PRRC2C PCLO TNRC6B	2.30e-05	199	76	5	c425e7975f492ed5cfcca022248adb627e1d27d4
ToppCell	3'_v3-blood-Lymphocytic_T_CD4-T_CD4/CD8\|blood / Manually curated celltypes from each tissue	PRRC2C TNRC6B HERC1 AGAP4	8.41e-05	135	76	4	ae2d3a42e567b5bade304c0caa497eb725be3565
ToppCell	ILEUM-non-inflamed-(3)_MNP-(3)_moDC\|(3)_MNP / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	NCOA3 TUT4 ATXN2 SYTL3	8.41e-05	135	76	4	b7a792a7c0c22d8b703509f134115f0e394d7de0
ToppCell	Hippocampus-Neuronal-Excitatory-eN1(Slc17a7)-eN1_1\|Hippocampus / BrainAtlas - Mouse McCarroll V32	LMO7 SUPT6H RUNX2 RTN4RL2	1.08e-04	144	76	4	e2a2f260f5ebaaef46248d199c407a15ce9d024a
ToppCell	10x5'-bone_marrow-Lymphocytic_T_CD4-T_CD4/CD8\|bone_marrow / Manually curated celltypes from each tissue	KMT2C SYTL3 MAML2 HERC1	1.47e-04	156	76	4	1545169694f686d28648a68b552c2ae606599d66
ToppCell	3'-GW_trimst-1-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	COL6A3 PROSER1 MAML2 AGAP4	1.78e-04	164	76	4	d167c7a987b9b35d1e7725c803df4f9cd5380e47
ToppCell	COPD-Lymphoid-ILC_B\|COPD / Disease state, Lineage and Cell class	SYTL3 TNRC6B RUNX2 MAML3	1.86e-04	166	76	4	7609671e453280c6e522e9f659c06aab8be81945
ToppCell	LPS-IL1RA-Epithelial_alveolar-Mes-like-AT2_Progenitor\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N DTNA CEP126 TFG	2.09e-04	171	76	4	ca2775a17b5c339c480a963953b6fa2b0731f24d
ToppCell	3'_v3-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8\|lymph-node_spleen / Manually curated celltypes from each tissue	TUT4 SYTL3 PRRC2C HERC1	2.09e-04	171	76	4	2e9a20f8980b78325c52065a9c14ab3656267c05
ToppCell	LPS-IL1RA-Epithelial_alveolar-Mes-like\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TC2N DTNA CEP126 TFG	2.09e-04	171	76	4	3ad4f138d9570500cfb4423a2be16bb7d1cacbf8
ToppCell	PND10-Immune-Immune_Myeloid-Granulocytic-Basophil-Basophil_mature\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	SYTL3 GPR34 RUNX2 HERC1	2.14e-04	172	76	4	c05af6e559f6af0fb15cefa03ffa1413e98a1a4a
ToppCell	PND10-Immune-Immune_Myeloid-Granulocytic-Basophil\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	SYTL3 GPR34 RUNX2 HERC1	2.14e-04	172	76	4	953b05f776348cff784e79c93df65841939d880f
ToppCell	5'-Adult-Distal_Rectal-Hematopoietic-Plasma_cells\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ANKRD13D RUNX2 RTN4RL2 SMAD4	2.18e-04	173	76	4	62abaaaf48cabd1423f17fb27c33b75ea88867f4
ToppCell	5'-Adult-Distal_Rectal-Hematopoietic-Plasma_cells-IgA_plasma_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ANKRD13D RUNX2 RTN4RL2 SMAD4	2.18e-04	173	76	4	09cd878c33534bd476d6a4880f5582076189da8c
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-kidney_interstitial_fibroblast_5\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	COL6A3 TC2N NAV2 MAML2	2.28e-04	175	76	4	910a075ccaf79de22338ecf321fa0a867f3d7d75
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	COL6A3 TC2N NAV2 MAML2	2.28e-04	175	76	4	f0c2eb82e17e8aec2cfa5d83169178f409cc1abc
ToppCell	COPD-Lymphoid-ILC_A\|World / Disease state, Lineage and Cell class	TC2N SYTL3 TNRC6B RUNX2	2.28e-04	175	76	4	e773e330de36f8a0aa9398a176ed7edb5599c582
ToppCell	COPD-Lymphoid-ILC_A\|COPD / Disease state, Lineage and Cell class	TC2N SYTL3 TNRC6B RUNX2	2.33e-04	176	76	4	484452cb38fe4604f0910a068361ed461b5b0c21
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c02-GPR183\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	TC2N SYTL3 MAML2 RUNX2	2.43e-04	178	76	4	31c847d7f7aa0f6d820afbb45d507992f5e9dc2f
ToppCell	3'-Distal_airway-Immune_Lymphocytic-Lymphocytic_T/NK-CD4-positive,_alpha-beta_T_cell-CD4_T_cells-CD4_T_cells_L.1.1.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TUT4 SYTL3 ARID2 PROSER1	2.49e-04	179	76	4	6bbb32d7e582a96cb3cfc3eb911b05d518e7d5e9
ToppCell	LA-01._Fibroblast_I\|LA / Chamber and Cluster_Paper	COL6A3 TC2N NFIA MAML2	2.49e-04	179	76	4	dcb6ec9ae72b13fe388b72dace2815293fafe8ee
ToppCell	10x5'-Liver-Lymphocytic_T_CD4-T_CD4/CD8\|Liver / Manually curated celltypes from each tissue	TC2N ARID2 TNRC6B HERC1	2.59e-04	181	76	4	f2315414e714ac86211546a935660c4be6e85f1b
ToppCell	pdx-Tumor_cells-T6\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	KLHL29 DTNA NAV2 MAML3	2.65e-04	182	76	4	7b24a4f712e1ae1525e8f1c8ec4e1fc43489cbee
ToppCell	IPF-Lymphoid-ILC_A\|World / Disease state, Lineage and Cell class	TC2N SYTL3 TNRC6B RUNX2	2.65e-04	182	76	4	f91bb45baaec76cb3bb26eedbcf0709b2492e93f
ToppCell	IPF-Lymphoid-ILC_A\|IPF / Disease state, Lineage and Cell class	TC2N SYTL3 TNRC6B RUNX2	2.70e-04	183	76	4	49bfeaae13eb236f61a5486ee75c39789936bb8a
ToppCell	droplet-Marrow-nan-3m\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NCOR1 TOB2 TUT4 PRRC2C	2.76e-04	184	76	4	1154a5ad7b8512272b7476f949ddac350910bfb7
ToppCell	Brain_organoid-organoid_Kanton_Nature\|Brain_organoid / Sample Type, Dataset, Time_group, and Cell type.	NCOR1 PRRC2C EPC1 DCC	2.82e-04	185	76	4	857c7ca8493e91ef1d0078ddafd6082020f9b169
ToppCell	Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte\|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	KMT2C PRRC2C PCLO MUC16	2.88e-04	186	76	4	23b8d51d20b05795a73892d3e20e0f9b6a207820
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	KLHL29 NFIA DTNA DCC	2.88e-04	186	76	4	b87acc80b7baa41681e4ed11d5537b9fbf5832f5
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	KMT2C ARID2 TNRC6B HERC1	3.00e-04	188	76	4	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Hematopoietic-T_cells-Activated_T\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TC2N SYTL3 GPR34 TASL	3.06e-04	189	76	4	c38157c8cf5c0c1f560011ef5cc5892a049ee2b7
ToppCell	COVID-19-kidney-PCT-S2\|kidney / Disease (COVID-19 only), tissue and cell type	KLHL29 SLC15A1 NFIA DTNA	3.06e-04	189	76	4	0be5c669b6b308bd98ddb70c84877c62a6244bbd
ToppCell	LV-01._Fibroblast_I\|World / Chamber and Cluster_Paper	COL6A3 TC2N NFIA MAML2	3.12e-04	190	76	4	12992ec80a7b4f4f17de693f0719ee061a9918fd
ToppCell	Control-Myeloid-cDC2\|Control / Disease state, Lineage and Cell class	SYTL3 RUNX2 TASL MAML3	3.12e-04	190	76	4	4e481e42353d47af7991744000403af2873f6a41
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL6A3 DTNA PRKD1 DCC	3.12e-04	190	76	4	841cd55861b43578d704418b9bc0af2e8b88323a
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL6A3 DTNA PRKD1 DCC	3.18e-04	191	76	4	b13229bb7f3713a392271aaf5dbae3edd1b9fe5a
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25\|PBMC_fresh-frozen / Compartment, severity and other cell annotations on 10x 3' data (130k)	TUT4 SYTL3 PRRC2C HERC1	3.18e-04	191	76	4	1ecd9849d14d5ebf3daf610e83fb50820cafd3ed
ToppCell	LV-02._Fibroblast_II\|World / Chamber and Cluster_Paper	COL6A3 TC2N NFIA MAML2	3.18e-04	191	76	4	d36565257ccba8c1bbed2c1c01be66a9cbb5f834
ToppCell	RV-01._Fibroblast_I\|World / Chamber and Cluster_Paper	COL6A3 TC2N NFIA MAML2	3.18e-04	191	76	4	70c067c54084bfb02c29bab085f4defd477194fb
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	TUT4 TC2N MAML2 RUNX2	3.18e-04	191	76	4	696921a4f160b6b55698652488ed781e855e5e51
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL6A3 DTNA NAV2 PRKD1	3.18e-04	191	76	4	6688cee34beee4f151ac17fccbc9c26a9aad72e1
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL6A3 DTNA PRKD1 DCC	3.24e-04	192	76	4	6f4ef24dab544681304b7f8a9dc073e7edaa4cf5
ToppCell	COPD-Myeloid-cDC2\|Myeloid / Disease state, Lineage and Cell class	JARID2 SYTL3 RUNX2 MAML3	3.24e-04	192	76	4	984cdc2f1d93e164bc946d63f58dacb629f82eb7
ToppCell	COPD-Lymphoid-T\|World / Disease state, Lineage and Cell class	TC2N SYTL3 EPC1 RUNX2	3.24e-04	192	76	4	eb4909574fb5fc91399463523e2737095773200a
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d02_child\|PBMC_fresh-frozen / Compartment, severity and other cell annotations on 10x 3' data (130k)	TUT4 PRRC2C HERC1 NUP153	3.24e-04	192	76	4	aee6522d25e012231cdb905ce047295cb64d6e82
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL6A3 DTNA NAV2 PRKD1	3.24e-04	192	76	4	99ce9e3c4c50cf64ebb62145f2b5420efa0db309
ToppCell	COPD-Lymphoid\|COPD / Disease state, Lineage and Cell class	TC2N SYTL3 TNRC6B RUNX2	3.24e-04	192	76	4	064fefb8212fadab0ff441f4bf643559b7fdb25d
ToppCell	Control-Lymphoid-T\|World / Disease state, Lineage and Cell class	TC2N SYTL3 TNRC6B RUNX2	3.24e-04	192	76	4	253cf4d2cf88ad8c45b73779336180840bef054b
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL6A3 DTNA PRKD1 DCC	3.24e-04	192	76	4	3d0cb19f037f604253d7d728689aeaa94251e92b
ToppCell	COPD-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	COL6A3 DTNA NAV2 MAML3	3.24e-04	192	76	4	62904f94dfce430456f05066522cbf9bd29f4d7e
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	NFIA DTNA MAML2 DCC	3.31e-04	193	76	4	9f69edc97b868d23998abc98928a2e89a885ef8a
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	JARID2 KMT2C MAML2 MAML3	3.31e-04	193	76	4	779276e775cb2492e8dd36436295a536084a6415
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL6A3 DTNA PRKD1 DCC	3.31e-04	193	76	4	fb28717fadd06c3840636d25409ce80c9254bd34
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-T-T_CD8-MAIT\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	TC2N SYTL3 GPR152 RUNX2	3.31e-04	193	76	4	9aeb34d7a24f84abff38d7b8cf0ec707c08eb27f
ToppCell	COVID-19_Mild\|World / Disease condition and Cell class	TUT4 SYTL3 PRRC2C LGALS9	3.31e-04	193	76	4	7256a5a491536c525b31ae96d47ab5c6303cb73a
ToppCell	RV-02._Fibroblast_II\|RV / Chamber and Cluster_Paper	COL6A3 TC2N NFIA MAML2	3.37e-04	194	76	4	11c79a8c56ece42713b04b321982e41e239f07a5
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	NFIA DTNA MAML2 DCC	3.37e-04	194	76	4	71d3c7448b1734de54187f902f65649f9283bd4c
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL6A3 DTNA PRKD1 DCC	3.37e-04	194	76	4	60622bd2f75bfe4c37f721cb12f03dab33f2f58d
ToppCell	LPS-antiTNF-Stromal_mesenchymal\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL6A3 DTNA PRKD1 DCC	3.37e-04	194	76	4	6e13549f697f7478b34fe71f7dd9d63c5d3db22e
ToppCell	nucseq-Immune-Immune_Myeloid-Myeloid_Dendritic\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	JARID2 SYTL3 RUNX2 TASL	3.37e-04	194	76	4	bde6830a281f7cd7fd1733e40a41ddd2673ba88e
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL6A3 DTNA PRKD1 DCC	3.37e-04	194	76	4	89b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCell	IPF-Multiplet-Multiplet\|IPF / Disease state, Lineage and Cell class	NFIA LMO7 NAV2 CEP126	3.44e-04	195	76	4	fce0c29574bb7aab181b9c00feb42681e285d1f2
ToppCell	COVID-19-Fibroblasts-Alveolar_FB\|COVID-19 / group, cell type (main and fine annotations)	COL6A3 DTNA NAV2 PRKD1	3.44e-04	195	76	4	603050beeb33c331d4b2e3fa46cae3f3e0e4bdc7
ToppCell	RV-02._Fibroblast_II\|World / Chamber and Cluster_Paper	COL6A3 TC2N NFIA MAML2	3.44e-04	195	76	4	ce90b30dcdb56d4cd925cdb79fd9d7cefd998f48
ToppCell	IPF-Multiplet\|IPF / Disease state, Lineage and Cell class	NFIA LMO7 NAV2 CEP126	3.44e-04	195	76	4	eacc0449ae6f3ad8002268cd061467684c6fb9a7
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	TUT4 SYTL3 PRRC2C TNRC6B	3.44e-04	195	76	4	ed5f772c82d4dfd1c8735224446ec9feae3fb8c2
ToppCell	(1)_T_cells-(1)_T_CD4_naive\|(1)_T_cells / Spleen cell shreds - cell class (v1) and cell subclass (v1)	TUT4 LMO7 TNRC6B CRTC1	3.44e-04	195	76	4	d3fa551bc6f5ee5890af1040415e61ecd5d46201
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D122\|Adult / Lineage, Cell type, age group and donor	COL6A3 DTNA NAV2 PRKD1	3.44e-04	195	76	4	aa0add081881d349099d12efca5cdee098038d4e
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	NAV2 PRKD1 MAML2 MAML3	3.51e-04	196	76	4	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	COPD-Lymphoid-T\|COPD / Disease state, Lineage and Cell class	TC2N SYTL3 EPC1 RUNX2	3.51e-04	196	76	4	30e53b8050d2a041f855d0e39bbd8f923c64c489
ToppCell	moderate-Lymphoid-Treg\|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	PRRC2C EPC1 TNRC6B RUNX2	3.51e-04	196	76	4	9152f4a8a27ff4ee28f231c5ad00eb2edd9ea6da
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	COL6A3 NFIA NAV2 MAML2	3.58e-04	197	76	4	85a8f1d18e0dd1d31341f5131eecd217553bf042
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	COL6A3 NFIA NAV2 MAML2	3.58e-04	197	76	4	e8e3ba791dfaa0fab35e0329a5e34376f9ee6143
ToppCell	Parenchyma_Control_(B.)-Immune-TX-MoAM-4\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	JARID2 RUNX2 AGAP4 SMAD4	3.58e-04	197	76	4	dc1c55e3aacc9d60d0f111c2f20f150ca296f011
ToppCell	Tracheal-10x3prime_v2-Immune_Myeloid-Dendritic_cell-DC_2\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	JARID2 GPR34 TASL LGALS9	3.58e-04	197	76	4	febafd8f0f5bb9a09f496f240e6b6b5e9275669b
ToppCell	nucseq-Immune-Immune_Myeloid-Myeloid_Dendritic-cDC2\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	JARID2 SYTL3 RUNX2 TASL	3.58e-04	197	76	4	a902aa05e5f711bcfdd9e19749ab636b597eb116
Drug	Isoconazole [27523-40-6]; Down 200; 9.6uM; PC3; HT_HG-U133A	NCOR1 NRSN2 HDAC6 EP400 ATXN2 TRIOBP HERC1	3.81e-06	196	75	7	2056_DN
Drug	Cephapirin sodium salt [24356-60-3]; Down 200; 9uM; HL60; HT_HG-U133A	NCOR1 TUT4 CELSR2 DTNA SUPT6H TNRC6B ZMYM3	4.07e-06	198	75	7	2730_DN
Drug	phenanthridinone; Up 200; 51.2uM; MCF7; HT_HG-U133A_EA	JARID2 TOB2 GGA2 DTNA SUPT6H MED12	4.25e-05	193	75	6	1115_UP
Drug	Triprolidine hydrochloride [550-70-9]; Down 200; 12.8uM; MCF7; HT_HG-U133A	ATXN2L UBAP2L DTNA TRIOBP TNRC6B MED12	4.50e-05	195	75	6	7408_DN
Drug	Ritodrine hydrochloride [23239-51-2]; Down 200; 12.4uM; MCF7; HT_HG-U133A	GTPBP2 GGA2 ADGRG2 DTNA TASL MED12	4.63e-05	196	75	6	5680_DN
Drug	Parbendazole [14255-87-9]; Up 200; 16.2uM; MCF7; HT_HG-U133A	COL6A3 TLK1 DTNA PCLO CRTC1 RUNX2	4.77e-05	197	75	6	3881_UP
Drug	Hydrocotarnine hydrobromide [5985-00-2]; Down 200; 13.2uM; MCF7; HT_HG-U133A	ATXN2L NCOR1 TLK1 DTNA SUPT6H MED12	4.90e-05	198	75	6	6827_DN
Drug	Dexamethasone acetate [1177-87-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A	TOB2 GTPBP2 GGA2 HDAC6 DTNA TNRC6B	4.90e-05	198	75	6	6271_DN
Drug	Methazolamide [554-57-4]; Down 200; 17uM; MCF7; HT_HG-U133A	NCOR1 DTNA SUPT6H PRRC2C TNRC6B SMAD4	5.04e-05	199	75	6	6268_DN
Drug	Probucol [23288-49-5]; Up 200; 7.8uM; PC3; HT_HG-U133A	ATXN2L GTPBP2 GGA2 TUT4 HDAC6 SLC15A1	5.04e-05	199	75	6	4666_UP
Drug	Ivermectin [70288-86-7]; Up 200; 4.6uM; PC3; HT_HG-U133A	GGA2 CELSR2 LMO7 DTNA PROSER1 SMAD4	5.04e-05	199	75	6	5853_UP
Disease	cerebral palsy (implicated_via_orthology)	AGAP7P AGAP4 AGAP6	1.65e-06	10	72	3	DOID:1969 (implicated_via_orthology)
Disease	Adenocarcinoma Of Esophagus	CRTC1 ARID1A SMAD4	4.97e-06	14	72	3	C0279628
Disease	spinocerebellar ataxia type 2 (implicated_via_orthology)	ATXN2L ATXN2	5.87e-06	2	72	2	DOID:0050955 (implicated_via_orthology)
Disease	depressive symptom measurement	KLHL29 PCLO PRKD1 BEND4 HERC1 DCC MAML3 MED12	9.44e-06	426	72	8	EFO_0007006
Disease	acute lymphoblastic leukemia, response to antineoplastic agent	NCOA3 CRTC1 MAML2	1.31e-05	19	72	3	EFO_0000220, GO_0097327
Disease	Intrahepatic Cholangiocarcinoma	KMT2C ARID1A SMAD4	2.72e-05	24	72	3	C0345905
Disease	Extrahepatic Cholangiocarcinoma	KMT2C ARID1A SMAD4	2.72e-05	24	72	3	C3805278
Disease	Cholangiocarcinoma	KMT2C ARID1A SMAD4	3.48e-05	26	72	3	C0206698
Disease	alcohol consumption measurement, waist-hip ratio	CRTC1 MAML2	3.51e-05	4	72	2	EFO_0004343, EFO_0007878
Disease	Klatskin's tumor (is_implicated_in)	KMT2C ARID1A	5.84e-05	5	72	2	DOID:4927 (is_implicated_in)
Disease	Adenoid Cystic Carcinoma	KMT2C TLK1 ARID1A MAML3	1.07e-04	100	72	4	C0010606
Disease	gastroesophageal reflux disease	ATXN2 CRTC1 DCC MAML3	1.11e-04	101	72	4	EFO_0003948
Disease	Prostatic Neoplasms	NCOA3 NCOR1 KMT2C HDAC6 ARID2 ARID1A MED12 ZMYM3	1.28e-04	616	72	8	C0033578
Disease	Malignant neoplasm of prostate	NCOA3 NCOR1 KMT2C HDAC6 ARID2 ARID1A MED12 ZMYM3	1.28e-04	616	72	8	C0376358
Disease	Carcinoma, Transitional Cell	NCOR1 KMT2C ARID1A	1.39e-04	41	72	3	C0007138
Disease	Carcinoma, Granular Cell	NCOA3 KMT2C PRKD1 ARID1A	1.90e-04	116	72	4	C0205644
Disease	Adenocarcinoma, Tubular	NCOA3 KMT2C PRKD1 ARID1A	1.90e-04	116	72	4	C0205645
Disease	Adenocarcinoma, Oxyphilic	NCOA3 KMT2C PRKD1 ARID1A	1.90e-04	116	72	4	C0205642
Disease	Carcinoma, Cribriform	NCOA3 KMT2C PRKD1 ARID1A	1.90e-04	116	72	4	C0205643
Disease	Adenocarcinoma, Basal Cell	NCOA3 KMT2C PRKD1 ARID1A	1.90e-04	116	72	4	C0205641
Disease	Adenocarcinoma	NCOA3 KMT2C PRKD1 ARID1A	1.90e-04	116	72	4	C0001418
Disease	influenza A severity measurement	CRTC1 MAML2	2.09e-04	9	72	2	EFO_0007743
Disease	Liver Diseases, Parasitic	KMT2C SMAD4	2.09e-04	9	72	2	C0023897
Disease	thiamine measurement	CRTC1 MAML2	2.61e-04	10	72	2	EFO_0010540
Disease	Colorectal Carcinoma	KMT2C LMO7 NPAP1 PRKD1 DCC ARID1A TFG SMAD4	3.09e-04	702	72	8	C0009402
Disease	peripheral arterial disease	CELSR2 ATXN2 SYTL3	3.16e-04	54	72	3	EFO_0004265
Disease	sexual dysfunction	EPC1 PRKD1	3.18e-04	11	72	2	EFO_0004714
Disease	autosomal dominant cerebellar ataxia (implicated_via_orthology)	ATXN2L ATXN2	3.81e-04	12	72	2	DOID:1441 (implicated_via_orthology)
Disease	Bladder Neoplasm	NCOR1 KMT2C ASXL2 ARID1A	3.89e-04	140	72	4	C0005695
Disease	Malignant neoplasm of urinary bladder	NCOR1 KMT2C ASXL2 ARID1A	4.00e-04	141	72	4	C0005684
Disease	Coffin-Siris syndrome	ARID2 ARID1A	4.50e-04	13	72	2	C0265338
Disease	brain cortex volume measurement	COL6A3 RUNX2	4.50e-04	13	72	2	EFO_0010287
Disease	neuroticism measurement, cognitive function measurement	KLHL29 ATXN2L PCLO NAV2 BEND4 DCC ARID1A	4.62e-04	566	72	7	EFO_0007660, EFO_0008354
Disease	caffeine measurement	CRTC1 MAML2	6.04e-04	15	72	2	EFO_0021177
Disease	severe acute respiratory syndrome, COVID-19	JARID2 COL6A3 SLC15A1 NFIA CRTC1 MAML2	7.85e-04	447	72	6	EFO_0000694, MONDO_0100096
Disease	cumulative dose response to bevacizumab	CRTC1 MAML2	9.77e-04	19	72	2	EFO_0005944
Disease	intrahepatic cholangiocarcinoma (is_marker_for)	ARID1A SMAD4	9.77e-04	19	72	2	DOID:4928 (is_marker_for)
Disease	heart failure	CELSR2 NFIA ATXN2 PRKD1	1.10e-03	185	72	4	EFO_0003144
Disease	neuroimaging measurement	ATXN2L NCOR1 NFIA ATXN2 PRRC2C NAV2 TNRC6B RUNX2 DCC	1.14e-03	1069	72	9	EFO_0004346
Disease	osteoarthritis, hip, osteoarthritis, knee, total joint arthroplasty	CRTC1 MAML2	1.20e-03	21	72	2	EFO_0004616, EFO_0010726, EFO_1000786
Disease	smoking cessation	KLHL29 ATXN2 BEND4 DCC MAML3	1.20e-03	325	72	5	EFO_0004319
Disease	left ventricular structural measurement	NFIA ATXN2 RUNX2	1.32e-03	88	72	3	EFO_0008205
Disease	wellbeing measurement	KLHL29 ATXN2 PCLO PRKD1 HERC1 DCC MAML3	1.49e-03	692	72	7	EFO_0007869
Disease	intraocular pressure measurement	COL6A3 ATXN2 LMO7 PCLO TRIOBP RUNX2	1.53e-03	509	72	6	EFO_0004695
Disease	cortical surface area measurement	KLHL29 ATXN2L NCOR1 NFIA ATXN2 PRRC2C NAV2 TRIOBP TNRC6B PRKD1	1.53e-03	1345	72	10	EFO_0010736
Disease	schizophrenia, intelligence, self reported educational attainment	CRTC1 PRKD1 MAML2 DCC MAML3	1.58e-03	346	72	5	EFO_0004337, EFO_0004784, MONDO_0005090
Disease	social interaction measurement	KLHL29 NFIA TNRC6B	1.59e-03	94	72	3	EFO_0009592
Disease	cognitive function measurement, self reported educational attainment	MTMR4 TRIOBP PRKD1 DCC MAML3	1.77e-03	355	72	5	EFO_0004784, EFO_0008354
Disease	Alzheimer disease, APOE carrier status	COL6A3 DCC PMS2CL	1.79e-03	98	72	3	EFO_0007659, MONDO_0004975
Disease	cerebellum cortex volume change measurement, age at assessment	CRTC1 MAML2	1.84e-03	26	72	2	EFO_0008007, EFO_0021497
Disease	unipolar depression, depressive symptom measurement	DCC MAML3	1.84e-03	26	72	2	EFO_0003761, EFO_0007006
Disease	eye measurement	ATXN2 HERC1	1.98e-03	27	72	2	EFO_0004731
Disease	Sezary Syndrome	KMT2C ARID1A	1.98e-03	27	72	2	C0036920
Disease	Bilateral Wilms Tumor	COL6A3 ARID1A	2.28e-03	29	72	2	C2930471
Disease	central nervous system cancer, glioma	CRTC1 MAML2	2.28e-03	29	72	2	EFO_0000326, EFO_0005543
Disease	longevity, healthspan, parental longevity	CELSR2 ATXN2	2.28e-03	29	72	2	EFO_0004300, EFO_0007796, EFO_0009762
Disease	pappalysin‐1 measurement	ATXN2 RTN4RL2	2.28e-03	29	72	2	EFO_0010618

Protein segments in the cluster

Peptide	Gene	Start	Entry
TSQEDPQFSVPPTAN	AGAP4	201	Q96P64
ASPSAPQSPSYQIQQ	EP400	46	Q96L91
ATPQQTSPAALPVFN	EPC1	351	Q9H2F5
PVQQAASPTNPTAIS	ANKRD13D	316	Q6ZTN6
QSNAVNPSRPAPTNT	C2orf78	761	A6NCI8
SANPTQPTVPQSAAS	C2orf78	796	A6NCI8
VTAAQQFAQSPNVTP	GTPBP2	356	Q9BX10
DQPPQNFSATPNVTT	GPR34	31	Q9UPC5
SSSEPPPQQFQAQSS	BEND4	71	Q6ZU67
SAPANVNTTSAPPVQ	ADGRG2	351	Q8IZP9
VQVQGQPNSSQPSPF	ARID2	1601	Q68CP9
NTAPQFQPPSYQATV	CELSR2	176	Q9HCU4
QPQSETKTTPSQAQP	ASXL2	751	Q76L83
SAQSPQSSFPQPAAV	ATXN2L	931	Q8WWM7
TSQEDPQFSVPPTAN	AGAP6	201	Q5VW22
DQSSPSQTQAAPQGP	C16orf46	126	Q6P387
PRDPSFVNIPQQTQS	NFIA	491	Q12857
PPTVSCQANNFSSVP	RTN4RL2	41	Q86UN3
QQPAPSTLSQQAAYP	ARID1A	566	O14497
VSQTNPPFQDEASSP	MUC16	4731	Q8WXI7
QSNNPAVVSAIPVPT	DCC	1241	P43146
NVVNPSSPSPNNSVL	PRKD1	506	Q15139
DSLSQAQTSQPPSPQ	KMT2C	1866	Q8NEZ4
QQPQTPRPSTQTDLF	KMT2C	2176	Q8NEZ4
AQQQIPSGSFAPSSQ	MAML3	1066	Q96JK9
TPASNTQSPQNSFPA	ATXN2	1206	Q99700
TQSPQNSFPAAQQTV	ATXN2	1211	Q99700
SFQNPRTVPVQPAFS	LGALS9B	146	Q3B8N2
SFQNPRTVPVQPAFS	LGALS9	146	O00182
PAQQAQTPVTTSPSA	HERC1	2626	Q15751
QQQSEAPTQTFPRTP	FAM90A27P	111	A6NNH2
AQQPSPAKPSAQQST	PCLO	541	Q9Y6V0
NNVVSTPAPSPDASQ	LMO7	951	Q8WWI1
PQADTNVQTPAPAAS	GPR152	406	Q8TDT2
QLSNTQPQPSTNIFG	MED12	2161	Q93074
APSPSSQNTPLAQVF	GGA2	461	Q9UJY4
PASPFGQSSVQTIQP	NRSN2	186	Q9GZP1
SSQNSPTGTPQQAQP	MTMR4	781	Q9NYA4
PSKPIQNQTFSTPAS	PROSER1	251	Q86XN7
PPTLGPSNNNNVATF	MAML2	911	Q8IZL2
SNPAPQIVQAASSAP	NDFIP2	126	Q9NV92
NQSPTSPVSNQGFSP	CRTC1	456	Q6UUV9
TNTANNSVPFVSSPP	CEP126	361	Q9P2H0
VNVPNNVTSSPTSNP	COL6A3	2856	P12111
TSQEDPQFSVPPTAN	AGAP7P	201	Q5VUJ5
SQPPQQRSAPDISFT	DTNA	451	Q9Y4J8
SQSPFAQSQVVVQAP	KPRP	26	Q5T749
SRQNPQSPPQDSSVT	HDAC6	16	Q9UBN7
SSTEIPPQCQPNFNT	SLC15A1	531	P46059
KFAQSQPNSPSTTPV	JARID2	116	Q92833
NSAPSPFNPQGQSQI	RUNX2	271	Q13950
QQNLPSSPAPSTIFS	SYTL3	266	Q4VX76
AAVPNSQNATISVPP	TC2N	31	Q8N9U0
NQVSSQTPQQPPTST	NCOR1	2066	O75376
QTPQQPPTSTFQNSP	NCOR1	2071	O75376
TANFPNIPVASTSQP	SMAD4	211	Q13485
QTQAFSPPPNVTASP	NCOA3	1276	Q9Y6Q9
AAQPVSSPAQTSLQP	NAV2	1296	Q8IVL1
SGLAFQQTSNTQPIP	PRRC2C	2506	Q9Y520
TQPFPTQFAPQILSQ	PRRC2C	2721	Q9Y520
NPFQDPSVTQLTNAP	SCAMP2	16	O15127
NSSITQPAPSFSQPV	NPAP1	391	Q9NZP6
QPAPSFSQPVQTTDS	NPAP1	396	Q9NZP6
QDNPQTSFPTCTPQR	TRIOBP	361	Q9H2D6
STTPQSAQAQPQPSS	SUPT6H	1641	Q7KZ85
PPTANNSQAPSTNSE	TLK1	351	Q9UKI8
SSPAPATTLAQPQQN	UBAP2L	871	Q14157
QPPQPSAATTLTSQQ	TIGD1	556	Q96MW7
TSQAPAPAFSGQPQQ	TFG	296	Q92734
TNPNPVFESPNLAAV	TASL	86	Q9HAI6
PTSQLPNAATAQPAV	SAP130	251	Q9H0E3
PTNIPFTSQAPAAFQ	SMAP1	326	Q8IYB5
PINANASFIPQVTQP	USF3	2076	Q68DE3
SSSSQPPVFGQQPSQ	NUP153	1366	P49790
VNNSPSPAPTFTSPQ	UBP1	321	Q9NZI7
SAASTSFQPQPVQPQ	ZNF207	121	O43670
FQVLPQPTNLTSPNT	PMS2CL	176	Q68D20
QPFPQNSSQSAAITQ	TUT4	1431	Q5TAX3
NFITANPAPQSQLSP	TOB2	241	Q14106
NSQSPESKPQTPSQT	ZMYM3	771	Q14202
AQVPPQFISPQVSAS	TNRC6B	1226	Q9UPQ9
VAQPPTFSPAVNVQA	KLHL29	166	Q96CT2